<SEC-DOCUMENT>0001178913-25-003403.txt : 20250929
<SEC-HEADER>0001178913-25-003403.hdr.sgml : 20250929
<ACCEPTANCE-DATETIME>20250929071222
ACCESSION NUMBER:		0001178913-25-003403
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20250929
FILED AS OF DATE:		20250929
DATE AS OF CHANGE:		20250929

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioLineRx Ltd.
		CENTRAL INDEX KEY:			0001498403
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35223
		FILM NUMBER:		251352213

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		2 HAMAAYAN STREET
		STREET 2:		MODI-IN TECHNOLOGY PARK
		CITY:			MODI-IN
		PROVINCE COUNTRY:   	L3
		ZIP:			ISRAEL
		BUSINESS PHONE:		972-8-642-9100

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		2 HAMAAYAN STREET
		STREET 2:		MODI-IN TECHNOLOGY PARK
		CITY:			MODI-IN
		PROVINCE COUNTRY:   	L3
		ZIP:			ISRAEL

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioLineRX, Ltd.
		DATE OF NAME CHANGE:	20100805
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2533810.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 25.8.1.5328
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">WASHINGTON, D.C. 20549</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">FORM 6-K</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">PURSUANT TO RULE 13a-16 OR 15d-16 OF</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">THE SECURITIES EXCHANGE ACT OF 1934</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">For the month of September 2025</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">Commission file number: 001-35223</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">BioLineRx Ltd.</div>
    <div style="text-align: center; line-height: 1.25;">(Translation of registrant&#8217;s name into English)</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">2 HaMa&#8217;ayan Street</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Modi&#8217;in 7177871, Israel</div>
    <div style="text-align: center; line-height: 1.25;">(Address of Principal Executive Offices)</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Form 20-F &#9746;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Form 40-F &#9744;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">On September 29, 2025, BioLineRx Ltd. (the &#8220;Company&#8221;) entered into a joint venture transaction (the &#8220;Joint Venture&#8221;) with Hemispherian AS, a Norwegian corporation (&#8220;Hemispherian&#8221;), for the
      development, clinical evaluation and commercialization of GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors (&#8220;GLIX1&#8221;). As part of the Joint Venture, (i) the Company and Hemispherian
      entered into a Collaboration and Shareholders Agreement (the &#8220;JV Agreement&#8221;), which governs the ownership, governance, funding, administration, and related operational and commercial terms of a newly-created company owned by the Company and
      Hemispherian (the &#8220;JV&#8221;), and (ii) Hemispherian and the JV entered into an Asset Transfer Agreement (the &#8220;ATA&#8221;), pursuant to which Hemispherian transferred to the JV certain intellectual property, regulatory filings, know-how, and related assets
      primarily in respect of GLIX1, Hemispherian&#8217;s lead compound (the &#8220;Transferred Assets&#8221;). The transactions closed on the same day.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Pursuant to the JV Agreement, Hemispherian will initially hold 60% of the issued share capital of the JV, and the Company will hold the remaining 40%. As consideration for Hemispherian&#8217;s contribution
      of the Transferred Assets, the Company has agreed to invest $5 million in the JV (the &#8220;Threshold Amount&#8221;) within 36 months as of the date of the JV Agreement, in tranches according to a development plan, which period may be extended by an additional
      six months upon the occurrence of certain events as specified in the JV Agreement (the &#8220;Threshold Term&#8221;). If the Company does not invest the full Threshold Amount by the end of the Threshold Term, Hemispherian will have the right to repurchase, for
      nominal consideration, a pro rata portion of the Company&#8217;s shares in the JV corresponding to the unfunded portion of the Threshold Amount.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Following the investment of the Threshold Amount, the Company may make additional investments in the JV. For each incremental $1 million invested by the Company beyond the Threshold Amount, the
      Company will be entitled to an additional 1% equity interest, up to an aggregate maximum ownership of 70%. Following the attainment of a 50% stake by the Company in the JV, Hemispherian will have the right to co-invest alongside the Company on the
      same terms in order to maintain a 50% ownership stake in the JV.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">
          <div style="line-height: 1.25;">Furthermore, under the terms of the JV Agreement, the Company will be responsible for managing and implementing the JV&#8217;s activities and overseeing the JV&#8217;s operations, budget, and expenses. Following the closing,
            the JV will pay Hemispherian a monthly advisory fee of $80,000 for a period of 24 months or until the termination of the JV, whichever occurs first.</div>
        </div>
      </div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">The JV Agreement provides for the establishment of a board of directors of the JV as well as a steering committee with joint representation from both the Company and Hemispherian. The Company holds the deciding vote
          in the event of any deadlock on either of such corporate bodies. In addition, the JV Agreement includes restrictions on the transfer of shares of the JV by the Company and Hemispherian, requiring the consent of the other party, subject to certain
          exceptions, including transfers to permitted transferees or transfers in connection with a merger or acquisition transaction. The JV Agreement further provides a bring-along right, which may be exercised by a simple majority of the shareholders
          and the board of directors, subject to the consent rights described above.</div>
      </div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">The JV has a first look right, as well as a right of first refusal, on other assets in Hemispherian&#8217;s pipeline for defined periods specified in the ATA.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">The ATA and the JV Agreement contain customary representations and warranties, indemnification and other provisions customary for transactions of this nature. In addition, the Company has provided an
      indemnification to Hemispherian in an amount of up to 50% of Hemispherian&#8217;s potential tax liability in Israel arising from the unlikely event of the payment of future dividend distributions by the JV to its shareholders, net of amounts recoverable
      under any double tax treaties available to Hemispherian.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">The JV Agreement and the ATA include termination events, including failure to fund the Threshold Amount within the Threshold Term, or prolonged inability of the JV to operate due to insufficient
      financial resources.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">The foregoing descriptions of the ATA and the JV Agreement are not complete and are qualified in their entirety by reference to the full text of such documents, copies of which are filed as exhibits
      to this Report on Form 6-K and are incorporated by reference herein.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">On September 29, 2025, the Company issued a press release entitled&#160;&#8220;BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA
      Damage Response in Glioblastoma and Other Tumors.&#8221; A copy of the press release is attached hereto as Exhibit 99.1.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">This Report on Form 6-K, including all exhibits hereto (other than the press release attached as Exhibit 99.1), is hereby incorporated by reference into all effective registration statements filed by
      the registrant under the Securities Act of 1933.&#160;</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <br>
    <div style="line-height: 1.25;">Attached hereto and incorporated by reference herein are the following exhibits:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="z8deece1b6a2f441aab7f532a7ba15e72" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 8%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25; font-weight: bold;">Exhibit No.</div>
          </td>
          <td style="width: 2%; vertical-align: bottom;"><br>
          </td>
          <td style="width: 90.08%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25; font-weight: bold;">Description</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2%; vertical-align: bottom;"><br>
          </td>
          <td style="width: 90.08%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="exhibit_10-1.htm">10.1(1)(2)</a></div>
          </td>
          <td style="width: 2%; vertical-align: bottom;"><br>
          </td>
          <td style="width: 90.08%; vertical-align: bottom;">
            <div style="line-height: 1.25;"><a href="exhibit_10-1.htm">Asset Transfer Agreement, dated as of September 29, 2025, between Hemispherian AS and Tetragon Biosciences
                Ltd.</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2%; vertical-align: bottom;"><br>
          </td>
          <td style="width: 90.08%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="exhibit_10-2.htm">10.2(1)(2)</a></div>
          </td>
          <td style="width: 2%; vertical-align: bottom;"><br>
          </td>
          <td style="width: 90.08%; vertical-align: bottom;">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;"><a href="exhibit_10-2.htm">Collaboration and Shareholders Agreement, dated as of September 29, 2025, between BioLineRx Ltd., Tetragon
                  Biosciences Ltd. and Hemispherian AS</a></div>
              <a href="exhibit_10-2.htm"> </a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: bottom;" rowspan="1"><br>
          </td>
          <td style="width: 90.08%; vertical-align: bottom;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="exhibit_99-1.htm">99.1</a></div>
          </td>
          <td style="width: 2%; vertical-align: bottom;"><br>
          </td>
          <td style="width: 90.08%; vertical-align: bottom;">
            <div style="line-height: 1.25;"><a href="exhibit_99-1.htm">Press Release dated September 29, 2025</a></div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">
      <div style="line-height: 1.25;">(1)&#160; Portions of this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K. The Registrant undertakes to furnish a copy of all omitted schedules and exhibits to the SEC upon its request.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">(2)&#160;&#160; Portions of this exhibit (indicated by asterisks) have been omitted under rules of the SEC permitting the confidential treatment of select information. The Registrant agrees to furnish a copy of all omitted
        information to the SEC upon its request.</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
      <div style="text-align: justify; line-height: 1.25;"> <br>
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z3a1b2c27810f4101a58eadaed694d72b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="vertical-align: bottom;" colspan="2">
            <div style="line-height: 1.25; font-weight: bold;">BioLineRx Ltd.</div>
          </td>
          <td style="width: 10%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 36%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 10%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25;">By:</div>
          </td>
          <td nowrap="nowrap" style="width: 36%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">/s/ Philip A. Serlin</div>
          </td>
          <td style="width: 10%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 36%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Philip A. Serlin</div>
          </td>
          <td style="width: 10%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 36%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Chief Executive Officer</div>
          </td>
          <td style="width: 10%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">Dated: September 29, 2025</div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit_10-1.htm
<DESCRIPTION>ASSET TRANSFER AGREEMENT, DATED AS OF SEPTEMBER 29, 2025, BETWEEN HEMISPHERIAN AS AND TETRAGON BIOSCIENCES LTD.
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 25.8.1.5328
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <!--PROfilePageNumberReset%Num%1%%%-->
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div style="text-align: right;"><u><font style="font-weight: bold;">Exhibit 10.1</font></u><br>
  </div>
  <div style="text-align: right;"><u><font style="font-weight: bold;"> <br>
      </font></u></div>
  <div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Certain confidential information contained in this document, marked by brackets and asterisk ([***]), has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K, because
      the Company customarily and actually treats such information as private or confidential and the omitted information is not material.</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;"> <br>
    </div>
  </div>
  <div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">ASSET TRANSFER AGREEMENT</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">This <font style="font-weight: bold;">Asset Transfer Agreement</font> (this &#8220;<font style="font-weight: bold;">Agreement</font>&#8221;) is entered into as of September 29, 2025 (the &#8220;<font style="font-weight: bold;">Effective Date</font>&#8221;), by and between:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z12b0a417b05e48e4bcad661b1de1d782">

        <tr>
          <td style="width: -0.1pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">a.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">Hemispherian AS</font>, a Norwegian company incorporated and existing under the laws of Norway, with company number and primary business address at L&#248;renveien 73A, 0585 Oslo, Norway (&#8220;<font style="font-weight: bold;">Hemispherian</font>&#8221;); and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1fe2bc27a04348d6af20cd318b1ef879">

        <tr>
          <td style="width: -0.1pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">b.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">Tetragon Biosciences Ltd.</font>, a company incorporated and existing under the laws of the State of Israel and with its registered office at Modi&#8217;in Technology Park, 2 HaMa&#8217;ayan Street, Modi&#8217;in, 7177871,
              Israel (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;).</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 22pt; line-height: 1.25;">Each of the parties under the above may be referred to herein as a &#8220;<font style="font-weight: bold;">Party</font>&#8221; and together as the &#8220;<font style="font-weight: bold;">Parties</font>.&#8221;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 21.25pt; line-height: 1.25;"><font style="font-weight: bold;">Whereas</font>, Hemispherian and BioLineRx Ltd., a company established under the laws of the State of Israel with its offices at Modi&#8217;in
      Technology Park, 2 HaMa&#8217;ayan Street, Modi&#8217;in, 7177871, Israel (&#8220;<font style="font-weight: bold;">BioLine</font>&#8221;) are entering into a Collaboration and Shareholders Agreement with even date herewith (the &#8220;<font style="font-weight: bold;">Joint
        Venture Agreement</font>&#8221;) for the purpose of forming a company to fund, further develop, clinically evaluate and commercialize products based on the Lead Compound and other compounds, including the Secondary Compound and any of the Other Compounds
      (as such terms are defined herein) as may be selected by the Company; and</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 21.25pt; line-height: 1.25;"><font style="font-weight: bold;">Whereas</font>, Hemispherian desires to transfer to the Company all its rights, titles, and interests in the Transferred Assets (as defined
      herein), as part of its contribution to be made to the Company, in consideration for the issuance to Hemispherian of shares in the Company as contemplated in the Joint Venture Agreement; and</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 21.25pt; line-height: 1.25;"><font style="font-weight: bold;">Whereas</font>, the Company desires to accept the transfer of the Transferred Assets, all in accordance with the terms set forth herein;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">Now, therefore</font>, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties, intending to be legally bound,
      hereby agree as follows:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="8d183255ca8a45849198d3e3e996a046" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-weight: bold;">1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;"><font style="font-weight: bold;">Definitions and Interpretation.</font></td>
        </tr>

    </table>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z65781dd8820e4dd6a70bf8ba95b430df">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">1.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Definitions</u>. In this Agreement, the following capitalized terms shall have the definitions as follows, or as otherwise given in the provisions hereunder and/or under the Joint Venture Agreement:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z19be587920e7432ab0ca7d1c08cc01b6">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Action</font>&#8221; means any claim, action, cause of action, demand, lawsuit, arbitration, inquiry, audit, notice of violation, proceeding, litigation, citation, summons, subpoena, or investigation of any
              nature, civil, criminal, administrative, regulatory, or otherwise, whether at law or in equity.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9cf29f134cf14ee7990315fd95c6432e">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Affiliate</font>&#8221; shall have the meaning given in the Joint Venture Agreement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf2ff068c5b2e4e98afaaadee8def3691">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Applicable Law</font>&#8221; means any applicable federal, state, national, provincial, territorial, foreign or local law, common law, statute, ordinance, rule, regulation, code, circular, or order of any
              Governmental Authority, including any rules promulgated by a stock exchange or regulatory body.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd2b80a76390245fbb899f9f63509a73f">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Asset Transfer Closing</font>&#8221; shall have the meaning given to it under Section 8.1.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z94e1b8d5f1394a608d6bdf372c88305f">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.5</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Asset Transfer Closing Date</font>&#8221; means the date on which the Asset Transfer Closing takes place.</div>
          </td>
        </tr>

    </table>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">1</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb1b44bb9b11d4f79bb5068e2c79180d0">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.6</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">BioLine</font>&#8221; shall have the meaning given in the preamble of this Agreement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7721b3abf829490bb3fe65daadbe1c90">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.7</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Business Day</font>&#8221; means any day other than a Friday, Saturday, Sunday, or other day on which commercial banks in Norway or the State of Israel are required or authorized by Applicable Law to be closed,
              at any time between 9:00 a.m. and 5:00 p.m. in the time zone of the relevant jurisdiction.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z003580a2507b4a02823b5c7b2882f07a">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.8</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Business Information</font>&#8221; means business information owned by, held by or under the control of Hemispherian and/or its Affiliates at the Asset Transfer Closing in relation to the Lead Compound and the
              Secondary Compound consisting of (i) vendor/supplier lists, sales, marketing and promotional information; and (ii) market surveys, business plans and forecasts; all as set forth in the Virtual Data Room.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb891ff679bef4b3cab668924866487a7">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.9</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Claim</font>&#8221; shall have the meaning given to it in Section 6.3.1.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2523bbdc072d4c88af380d8f02873775">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.10</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Closing Conditions</font>&#8221; shall have the meaning given to it in Section 8.1.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze1a151dd975b4989b664f2c0bb8a6ea9">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.11</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Company</font>&#8221; shall have the meaning given in the preamble of this Agreement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z289754a4676d41b69fc94e447dda00b4">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.12</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Compliance Confirmation</font>&#8221; shall have the meaning given to it in Section 8.1.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z032d68de985d414d97bf97b94dfa0516">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.13</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Compounds</font>&#8221; means all the Lead Compound, the Secondary Compound and the Other Compounds.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9c7ab060d55744cb81e5328fd47029c4">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.14</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Designated Chairpersons</font>&#8221; shall have the meaning given to it in Section 11.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd500cef19726475bb0a481d638d34d59">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.15</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Dispute</font>&#8221; shall have the meaning given to it in Section 11.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbce57f31ea904af297581e30d853bdc3">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.16</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">DVD ROM</font>&#8221; means the read only memory disk produced by Hemispherian which contains a copy of all the documents and materials uploaded to the Virtual Data Room as of the Asset Transfer Closing Date.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z147527ff724c450aa8275db69d787fa6">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.17</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Encumbrance</font>&#8221; means with respect to any security, property or asset, as the case may be, any mortgage, lien, pledge, charge, security interest, encumbrance, hypothecation, option, easement, trust,
              equitable interest, proxies, right of first refusal, defect in title, impediment of title, impairment of title, preemptive right or restrictions or rights of third parties of any nature (including any spousal community property rights, any
              restriction on the voting, transfer, receipt of any income derived from, the possession of any security, or the exercise or transfer of any other attribute of ownership of a security).</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zde534bb90e5a4992a36b40debf0010a8">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.18</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Excluded Liabilities</font>&#8221; means the Liabilities relating to the Transferred Assets and outstanding or accrued or referable to the period on or before the Asset Transfer Closing Date or arising by virtue
              of the transfer of the Transferred Assets recorded by this Agreement, including (i) the Liabilities to creditors of Hemispherian including all Tax Liabilities of Hemispherian, (ii) the Liabilities of Hemispherian in respect of the Transferred
              Assets under the Applicable Law, and (iii) any and all Third Party claims in respect of the Transferred Assets attributable to Hemispherian, each in respect of the period ending on the Asset Transfer Closing Date.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7e966c3abf3f4167a11b35102f00efde">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.19</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Governmental Approvals</font>&#8221; means all permits, approvals, authorizations, registrations, certificates, consents, and similar rights (including without limitation those in connection with the export
              control of technology or technical data under any Applicable Law, if applicable) required to be obtained from Governmental Authorities for the assignment and transfer of the Transferred Assets contemplated under this Agreement.</div>
          </td>
        </tr>

    </table>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7014e6d90e1840f7bdba12271f522cb6">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.20</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Governmental Authority</font>&#8221; means any central, state, federal, city, municipal, foreign or local governmental or quasi-governmental authority of any nature (including any governmental agency, branch,
              bureau, department or other entity and any court or other tribunal), any authority, regulator, body or other organization exercising, or entitled to exercise, any administrative, executive, judicial, legislative, police, regulatory or taxing
              authority or power of any nature, and any official of any of the foregoing in any jurisdiction of the world.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z93851816fea74df4803cdf0ef4510ef6">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.21</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Governmental Order</font>&#8221; means any order, writ, judgment, injunction, decree, stipulation, determination, or award made by or with any Governmental Authority.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z79462a2493b34ce7ae8004523700274e">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.22</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Hemispherian</font>&#8221; shall have the meaning given in the preamble of this Agreement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2dd48fbc8bd8468cb8a1c557158b39ac">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.23</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">ICC</font>&#8221; shall have the meaning given to it in Section 11.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6b5a27e6d3f547768f144c41c17a2782">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.24</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Indemnifiable Loss(es)</font>&#8221; means, with respect to any Person, any action, cost, direct damage, disbursement, expense, liability, loss, obligation, penalty, or settlement (if such settlement is approved
              by the indemnifying Party) of any kind or nature, no matter foreseeable or not. Notwithstanding anything to the contrary provided in the preceding sentence, &#8220;Indemnifiable Loss(es)&#8221; shall include, but shall not be limited to, (i) interest or
              other costs, penalties, legal, accounting and other professional fees and expenses reasonably incurred in the investigation, collection, prosecution or defense of claims and amounts paid in settlement, that have been imposed on or otherwise
              incurred or suffered by such Person; and (ii) any taxes that have been payable by such Person directly by reason of the indemnification of any Indemnifiable Loss hereunder (e.g., VAT or similar transaction-based taxes levied directly on the
              indemnification payment), other than taxes that would have been payable notwithstanding the event giving rise to indemnification or which are generally levied on income.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z844c7476b793475499f8ee082dd6bc10">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.25</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Intellectual Property</font>&#8221; means any and all rights in, arising out of, or associated with any of the following in any jurisdiction throughout the world: (a) issued patents and patent applications
              (whether provisional or non-provisional), including divisional, continuations, continuations-in-part, substitutions, reissues, reexaminations, extensions, or restorations of any of the foregoing, and other Governmental Authority-issued
              indicia of invention ownership (including certificates of invention, petty patents, and patent utility models) (&#8220;<font style="font-weight: bold;">Patents</font>&#8221;); (b) trademarks, service marks, brands, certification marks, logos, trade
              dress, trade names, and other similar indicia of source or origin, together with the goodwill connected with the use of and symbolized by, and all registrations, applications for registration, and renewals of, any of the foregoing (&#8220;<font style="font-weight: bold;">Trademarks</font>&#8221;); (c) copyrights and works of authorship, whether or not copyrightable, and all registrations, applications for registration, and renewals of any of the foregoing; (d) websites and domain names;
              (e) industrial designs, and all Patents, registrations, applications for registration, and renewals thereof; (f) trade secrets, inventions (whether or not patentable), discoveries, improvements, technology, business and technical information,
              data, databases, data compilations and collections, specifications, records, tools, methods, processes, formulae, formulation, techniques, and other confidential and proprietary information and all rights therein (&#8220;<font style="font-weight: bold;">Know-How</font>&#8221;); (g) computer programs and code; and (h) all other intellectual or industrial property and proprietary rights.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z43b0fcd18a3f4d2691745efcaa09f3d3">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.26</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">IP Transfer Documentation</font>&#8221;<font style="font-weight: bold;">&#160;</font>means all documents to be executed, provided or issued by Hemispherian and the Company in a form required under the Applicable Law
              for filing with the relevant Governmental Authorities in order to effect the title transfer of the Registered IP from Hemispherian to the Company in each jurisdiction where the Registered IP is filed or registered.</div>
          </td>
        </tr>

    </table>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">3</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z961baf54481a44eabacba1b706861aa1">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.27</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Joint Venture Agreement</font>&#8221; shall have the meaning given to it in the recitals of this Agreement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2a7b2f5b36bc4ca08a5d1971f685b959">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.28</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">JV Business</font>&#8221; means the development, clinical evaluation, and commercialization of products based on the Lead Compound and other compounds, including the Secondary Compound and any of the Other
              Compounds, as may be selected by the Company in accordance with the terms of this Agreement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4dd025884fcb4dd381dc79419a784e59">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.29</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Know-How</font>&#8221; shall have the meaning set out in the definition of &#8220;Intellectual Property.&#8221;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zae38fdf0da524f84bcc96ee0b8aed3c8">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.30</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Lead Compound</font>&#8221; means Hemispherian&#8217;s GLIX1 compound for the treatment of glioblastoma and other indications.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z99f6e6dcf6664f3e8a5322b63b6dcecd">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.31</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Liabilities</font>&#8221; means any claim, debt, cost, expense, direct damage (including interest, penalties and legal costs and all other professional costs and expenses), liability, or obligation, whether
              secured or unsecured, fixed, absolute, contingent, or otherwise, and whether due or yet to become due, but excluding any loss of profit, loss of reputation or loss of value.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z16f71e7919274d5d9acecd7b1a3e7ebb">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.32</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">License Back</font>&#8221; shall have the meaning given to it in <u>Appendix A</u> hereto.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4223cd30a02a446db483617539f3332b">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.33</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Other Compounds</font>&#8221; means Hemispherian&#8217;s compounds <font style="font-style: italic;">other than</font> the Lead Compound and the Secondary Compound which are set out in <u>Schedule 1</u> attached
              hereto.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za93722cbff0b44af9159e2877912774a">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.34</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Option</font>&#8221; shall have the meaning given to it in Section 10.2.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4f32fa0e96c54239a3815b5a70581065">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.35</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Option Period</font>&#8221; shall have the meaning given to it in Section 10.2.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8e92c761d16b4bc5b7e119802c6c6b92">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.36</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Patents</font>&#8221; shall have the meaning set out in the definition of &#8220;Intellectual Property.&#8221;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0f941960c4704d65b5fab77e5c866653">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.37</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Person</font>&#8221; means any natural person, limited liability company, joint stock company, joint venture, partnership, enterprise, trust, unincorporated organization or any other entity or organization.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc59d32934ddc4612ba4c1b4084dacba9">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.38</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Project</font>&#8221; means that certain research project relating to the Secondary Compound which is supported by funding from the Research Council of Norway (the &#8220;<font style="font-weight: bold;">RCN</font>&#8221;)
              and which is designated as RCN Project Number [***].</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z60f5191a2dbc4101921890eff4759441">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.39</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Registered IP</font>&#8221; means, collectively, the Transferred Patents and Transferred Trademarks.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc6a6812982a34c1ea1b52ac25e4fde7c">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.40</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Registered IP Deliverables</font>&#8221; shall mean the following documents with respect to the Registered IP, including originals or comparable electronic or other copies if they exist: (i) a complete list of
              the Registered IP with the applicable filing and registration details, together with the original registration certificates, and electronic copies of filing and prosecution history, office actions and other related documentation; (ii)
              complete details of Hemispherian&#8217;s agents then currently responsible for management of the Registered IP; and (iii) a list of all pending actions and deadlines either overdue or falling due with respect to the Registered IP.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcf1609b78d174e3196ee7777f9940335">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.41</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Regulatory Information</font>&#8221; means the following information listed under the &#8220;Regulatory Information&#8221; part of <u>Schedule 4</u> attached hereto: (a) all material information, documents and materials
              related to all applications filed by Hemispherian with any Governmental Authorities in relation to the Lead Compound and the Secondary Compound in any jurisdiction of the world as at Asset Transfer Closing; and (b) all material regulatory
              submissions, correspondence, summaries of discussions and minutes of meetings with, feedback from, and notices, opinions, responses and approvals received from any Governmental Authorities in relation to the foregoing; all as previously
              provided by Hemispherian to BioLine and uploaded in the Virtual Data Room. Regulatory Information includes the IND for the Lead Compound filed by Hemispherian with the US Food and Drug Administration.</div>
          </td>
        </tr>

    </table>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">4</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf4fda9ca82f54e08bfe405389ee05c8d">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.42</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Secondary Compound</font>&#8221; means Hemispherian&#8217;s GLIX5 compound for the treatment of glioblastoma and other indications.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z29c41e1c50f44c61aed57f1f9211d4f0">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.43</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Secondary Compound Restricted Data</font>&#8221; means all data, results, information and related intellectual property generated or arrived at during Hemispherian&#8217;s performance of the Project.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z79df1d42a5874fa784c178fc6430f598">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.44</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Selection Notice</font>&#8221; shall have the meaning given to it in Section 10.2.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc83e4fb7550a436e9a2b69b644c8173d">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.45</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Third Party</font>&#8221; shall mean any Person other than the Parties and their Affiliates.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6898dcde382241ada7cf5f673be064f6">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.46</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Trademarks</font>&#8221; shall have the meaning set out in the definition of &#8220;Intellectual Property.&#8221;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6b23369d784142608ddd952f8cf22aa8">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.47</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Transferred Assets</font>&#8221; shall mean the Transferred IP, Regulatory Information and Business Information.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8c58f38a4de14094852b8f7ffd4c3c1a">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.48</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Transferred Contracts</font>&#8221; shall have the meaning given to it in Section 9.<u>8</u>.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf7141fabdaed4db185ba216d97cdb846">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.49</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Transferred IP</font>&#8221; means the Registered IP and Transferred Know-How.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5a27e2afcb9148528081cce0110c261f">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.50</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Transferred Know-How</font>&#8221; means all Know-How owned, held or controlled by Hemispherian and/or its Affiliates (including without limitation any Know-How, whether in paper or electronic format, that is
              held or possessed by Hemispherian or any service provider of Hemispherian or other Third Party on behalf of or for the benefit of Hemispherian, or to which Hemispherian has rights) at the Asset Transfer Closing in relation to the inventions
              claimed under the Transferred Patents and the Compounds, as listed under the &#8220;Transferred Know-How&#8221; part of <u>Schedule 4</u> attached hereto. Transferred Know-How includes: (i) technology applications, historical and current data, documents
              and original records, including raw data, from technology and product research, development, testing, manufacturing and quality control; (ii) Chemical, Manufacturing and Control (CMC) information, including without limitation, information
              regarding active pharmaceutical ingredients (APIs) and drug product (DP); raw materials, excipients, packaging, specifications (release and IPCs), development reports, process development reports, formulation development report, API
              characterization studies, qualification of reference standard, analytical method development reports, analytical methods validation protocols and reports, manufacturing process and in process control methods, batch records and related files
              (MBRs, EBRs, change controls and deviations), release files (COAs, COCs and BSE/TSE), production analytical test records (QC data and results), stability study protocols and reports and IND CMC sections; (iii) materials of preclinical studies
              (cell cultures (in vitro) and/or animal models (in vivo) and/or ex-vivo) (including without limitation pharmacology, pharmacokinetics (PK), bioavailability (BA), pharmacodynamics (PD), ADME (absorption, distribution, metabolism, and
              excretion) and toxicology/&#160;nonclinical safety studies), consisting of protocols, raw data, results and reports of such studies; (iv) protocols, raw data, results, reports and other materials for clinical studies and trials, to the extent
              relevant. The Transferred Know-How excludes Secondary Compound Restricted Data.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za9b0cfb25b3d4677bd1cc3346f4d8ada">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.51</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Transferred Patents</font>&#8221; means the Patents listed in <u>Schedule 2</u> attached hereto, including any pending applications as listed in such schedule.</div>
          </td>
        </tr>

    </table>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">5</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5bf304b7d05f44b880fe0d0d67e7ccc0">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.52</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Transferred Trademarks</font>&#8221; means all Trademarks owned, held, or controlled by Hemispherian and/or its Affiliates in relation to the Transferred IP, as listed in <u>Schedule 3</u> attached hereto.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze747c47be7054e478099ea810401bb16">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">1.1.53</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Virtual Data Room</font>&#8221; shall mean the electronic / virtual data room administered by Ideals Virtual Data Room with respect to the transactions contemplated hereunder, which shall remain accessible for a
              period 12 months from the Effective Date through the following link: [***] and which shall enable downloading of all uploaded materials.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0eefea6bc6d44aa9923ebcadb2a5ec01">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">1.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Interpretation</u>. When a reference is made in this Agreement to Sections, Schedules or Appendices, such reference shall be to a Section of, or a Schedule or Appendix to, this Agreement unless otherwise indicated. The headings
              contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. The words &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; when used herein shall be deemed in each case to be
              followed by the words &#8220;without limitation.&#8221; When calculating the period of time before which, within which or following which any act is to be done or step taken pursuant to this Agreement, the date that is the reference date in calculating
              such period shall be excluded. References to any agreement, contract or document are references to that agreement, contract or document as may be amended, restated, consolidated, supplemented, novated, replaced or otherwise modified from time
              to time. Unless the context of this Agreement otherwise requires: (i) words of any gender include each other gender; (ii) words using the singular or plural number also include the plural or singular number, respectively; and (iii) the terms
              &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereunder&#8221; and derivative or similar words refer to this entire Agreement; (iv) all references to &#8220;$&#8221; shall be denominated in U.S. dollars; and (v) unless indicated otherwise, all mathematical calculations contemplated
              hereby shall be rounded to the hundredth decimal place.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z08928cbae6e34361b382994792be634e">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-weight: bold;">2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-weight: bold;">Transfer of Assets and License Back.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zaf80fd7efcfb4f398657360e451197ed">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">2.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Subject to the terms and conditions of this Agreement, upon the Asset Transfer Closing, Hemispherian shall irrevocably transfer, assign, and convey to the Company all rights, titles, and interests in and to the Transferred Assets
              (including all rights to sue, license, collect and receive all incomes, royalties, damages, payments due, injunctive relief and any other settlements or remedies including in any causes of action for past, present or future infringements to
              the extent related to the Transferred Assets), free and clear of any Encumbrance, with effect from the Asset Transfer Closing Date. On the Asset Transfer Closing Date, and except as expressly outlined herein, the Company obtains all rights,
              titles, and interests and assumes all obligations with respect to the Transferred Assets, provided that any Excluded Liabilities remain the sole responsibility of Hemispherian.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z46ac143fe86348299dc4b427faaa2cb7">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">2.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Hemispherian will, in accordance with its normal practice, pay, satisfy or discharge all Liabilities relating in any way to the Transferred Assets which are not expressly transferred to the Company hereunder. If the Company becomes aware
              after Asset Transfer Closing that Hemispherian has failed to discharge any such Liabilities and believes that this failure may damage the value of the Transferred Assets as owned or held by the Company after Asset Transfer Closing, the
              Company may give notice of that fact to Hemispherian. If Hemispherian does not provide evidence that the Liability in question is disputed on reasonable grounds, the Company may satisfy such Liability on Hemispherian&#8217;s behalf and shall be
              entitled to immediate reimbursement from Hemispherian of the amount paid by the Company.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zae6e490bb6394d999fab9140f8af85d7">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">2.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Immediately following the Asset Transfer Closing, and subject to the terms and conditions of this Agreement, the Company shall grant to Hemispherian the License Back.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfa697f280c8f4ecb94e470457ac77c08">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-weight: bold;">3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">Consideration. </font>As the sole consideration for the transfer by Hemispherian to the Company of the Transferred Assets, the Parties acknowledge that the Company will issue shares to Hemispherian
              pursuant to the terms of the Joint Venture Agreement.</div>
          </td>
        </tr>

    </table>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">6</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z057d2fe2901147a2883b5b4b3204c31e">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-weight: bold;">4.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">Representations and Warranties of Hemispherian.</font> Hemispherian hereby represents and warrants to the Company that each statement contained in this Section 4 is true and accurate as of the date of this
              Agreement, and will be true and accurate as of the Asset Transfer Closing Date (as though made then and as though the Asset Transfer Closing Date was substituted for the Effective Date throughout this Section 4), except to the extent any
              statement expressly speaks as of a specific date, in which case as of such specific date, and except to the extent agreed by the Parties in writing to update any statement contained in this Section 4 as of the Asset Transfer Closing Date:</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze045bfee4dd64aaabb0159597bbedd49">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">4.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Completeness</u>. The Registered IP as defined and specified in this Agreement constitutes all and the complete Intellectual Property that Hemispherian has filed for or registered with any Governmental Authority or other registry in any
              jurisdiction as of the Asset Transfer Closing. <u>Schedule 1</u> and <u>Schedule 2</u> attached hereto contain a correct, current and complete list of all Registered IP, specifying as to each, as applicable: the title or mark; the
              jurisdiction by or in which it has been issued, registered or filed; the patent registration and/or application serial number; the issue, registration and/or filing date; the Hemispherian entity which is the record owner; the current status;
              and anticipated expenses and filing fees due during the upcoming 6-month period. Other than as contained in <u>Schedule 1</u> and <u>Schedule 2</u>, Hemispherian has not made any other Patent, Trademark or other Intellectual Property
              application or filing related to the Transferred IP. The Transferred Know-How as defined and specified in this Agreement constitutes all and the complete unregistered Intellectual Property relating to the Transferred IP, and Hemispherian is
              aware of no other unregistered Intellectual Property relating to the Transferred IP. Regulatory Information and Business Information as defined and specified in this Agreement constitute all and the complete regulatory and business
              information that is material to the Transferred IP at Asset Transfer Closing.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2c62fcac88794473be04398372b6a1e2">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">4.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Title</u>. Hemispherian is the sole and exclusive legal and beneficial owner of all right, title and interest to the Transferred Assets; <font style="font-style: italic;">provided, however</font>, that for documents and correspondence
              included within the scope of the definition of &#8220;Transferred Assets&#8221; that are, by their nature, not subject to ownership (such as, by way of example, correspondence with regulatory agencies within the Regulatory Information), Hemispherian is
              the sole and exclusive controller of such Transferred Assets; in particular, with respect to the Registered IP, Hemispherian is the sole and exclusive record owner of all right, title and interest in and to the Registered IP. The Transferred
              Assets are free and clear of all Encumbrances, and Hemispherian has received all necessary and required approvals and consents from all relevant third parties to the transfer of the Transferred Assets to the Company. All assignments and other
              instruments necessary to establish, record and perfect Hemispherian&#8217;s ownership, rights, title and/or interest in the Transferred IP have been validly executed, delivered, and filed with the relevant Governmental Authorities in accordance
              with the Applicable Law in each respective jurisdiction, as applicable. Hemispherian has entered into binding, valid and enforceable written contracts with each current and former employee and independent contractor who is or was involved in
              or has contributed to the invention, creation or development of any Transferred IP during the course of employment or engagement with Hemispherian whereby such employee or independent contractor (i) acknowledges Hemispherian&#8217;s exclusive
              ownership of all right, title and/or interest in and to the Transferred IP invented, created or developed by such employee or independent contractor within the scope of their employment or engagement with Hemispherian; (ii) grants to
              Hemispherian a present, irrevocable assignment of any ownership and other interest such employee or independent contractor may have in or to such Transferred IP; and (iii) irrevocably waives any right or interest, including any moral rights,
              regarding such Transferred IP and Regulatory Information, to the extent permitted by Applicable Law. Hemispherian has received all required assignments transferring and assigning the Transferred IP to Hemispherian duly executed by all
              inventors thereof.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z05c670d122b2442498e3f6835bb1bd02">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">4.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Right to Own and Use</u>. Neither the execution, delivery, or performance of this Agreement, nor the consummation of the transactions contemplated hereunder, will result in the loss or impairment of or payment of any additional amounts
              with respect to, or require the consent of any other Person in respect of, the Company&#8217;s right to own or use any Transferred IP and Regulatory Information in its conduct of business. Immediately following the Asset Transfer Closing, all
              Transferred IP and Regulatory Information will be available for use by the Company on the same terms as they were available for use by Hemispherian immediately prior to the Asset Transfer Closing. Upon transfer of the Transferred IP and
              Regulatory Information pursuant to this Agreement, the Company will own all right, title and interest to such Transferred IP and Regulatory Information on the same terms as they were owned by Hemispherian immediately prior to the transfer of
              such Transferred IP and Regulatory Information.</div>
          </td>
        </tr>

    </table>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">7</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfbc073a4ebfc47918597d8438893dbbc">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">4.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Validity and Enforceability</u>. All of the Registered IP is valid and enforceable and are subsisting and in full force and effect. Hemispherian has taken all necessary and reasonable steps to maintain and enforce the Registered IP and
              to preserve the confidentiality of all trade secrets or confidential information within Transferred Know-How and Regulatory Information, including by requiring all Persons having access thereto to execute binding, written non-disclosure
              agreements, or ensuring that such Persons are otherwise subject to obligations of confidentiality and non-disclosure. All renewal, application and other official registry fees and steps required for the prosecution, maintenance, protection,
              and enforcement of the Registered IP have been timely paid or taken, and there are no outstanding payments in respect of the prosecution, maintenance, protection, and enforcement of the Registered IP.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8776b2449b604b2d838a053e46db7c44">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">4.5</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Non-Infringement</u>. To Hemispherian&#8217;s best knowledge, the Transferred Assets do not infringe, misappropriate, make unauthorized use of, or otherwise violate, and have not infringed, misappropriated, made unauthorized use of, or
              otherwise violated, the Intellectual Property or other rights of any Person.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z01218ef799444ee0bff459b317b837cc">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">4.6</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>No Actions</u>. There are no Actions (including without limitation any withdrawal, opposition, cancellation, revocation, invalidation, rejection, deregistration, review or other proceeding), whether settled, in progress, pending or, to
              Hemispherian&#8217;s best knowledge, threatened (including in the form of offers to obtain a license): (i) alleging any infringement, misappropriation or other violation of the Intellectual Property of any Person by Hemispherian in its use of the
              Transferred Assets; or (ii) challenging the validity, enforceability, registrability, patentability, ownership, right, title or interest in and to any Transferred IP or Regulatory Information. Hemispherian is not aware of any facts or
              circumstances that could reasonably be expected to give rise to any such Action. Hemispherian is not subject to any outstanding Governmental Order (including, to Hemispherian&#8217;s best knowledge, any prospective Governmental Order or any motion
              or petition therefor) that does or could reasonably be expected to restrict or impair the use of any Transferred IP or Regulatory Information.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z58769ff6aeed41c98ac497308e77e8b6">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">4.7</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Infringement Actions</u>. There are no Actions by Hemispherian or, to Hemispherian&#8217;s best knowledge, by any other Person alleging any infringement, misappropriation, or other violation by any Person of any Transferred IP or Regulatory
              Information.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z13344792df7945d79d0b2d813b31d4ee">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">4.8</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>No Restrictions on Rights</u>. The Company will not be subject to any covenant not to sue or similar restrictions on its enforcement or enjoyment of the Transferred Assets as a result of any prior transaction related to the Transferred
              Assets.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z15ee4681cfe449d8b2cf32b5a2034419">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">4.9</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Regulatory Matters</u>. None of the Transferred Assets involves the maintenance or collection, directly or indirectly, of &#8220;sensitive personal data&#8221; of U.S. or EU citizens within the meaning of applicable privacy and data security laws
              and regulations.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z34aea12d32fa4191b336f6c4fa1d2272">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">4.10</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Accuracy of Information Provided</u>. All information, documentation and other materials provided or disclosed by Hemispherian to the Company in relation to the Transferred Assets, including without limitation, any fact, matter or
              circumstance set forth in this Agreement, contained in the Virtual Data Room, and/or provided through email or by other means by Hemispherian, are true and accurate in all material respects and not misleading, and Hemispherian is not aware of
              any fact, matter or circumstances not provided which renders any such information untrue, inaccurate or misleading in any material respect.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd47addb777e349b4bdda851a7dfb57f6">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">4.11</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Totality of Compounds</u>. The Compounds constitute the entirety of compounds that Hemispherian has developed and has in development as of the Effective Date.</div>
          </td>
        </tr>

    </table>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">8</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z25ee95a9c98c4c26bec5f991868532ff">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-weight: bold;">5.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">Representations and Warranties of the Parties. </font>Each Party hereby represents and warrants to the other Party as of the date of this Agreement and as of the Asset Transfer Closing Date that (i) such
              Party is a company duly formed and validly existing under the laws of the jurisdiction of its formation, such Party has the full power and authority and has taken all actions required and obtained all corporate authorizations, Third Party
              consents, approvals, and/or other authorizations and Governmental Approvals required to enter into this Agreement and to carry out its obligations hereunder; and (ii) the execution of this Agreement and the performance of obligations
              hereunder will not (a) violate the articles of association or any other constitutional documents of such Party, (b) conflict with, result in a breach of, or constitute a default under any agreement or instrument by which such Party is bound
              or (c) violate any provision of Applicable Law or requirements of any stock exchange applicable to such Party.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9d36ec698314446e91fec265b3926a7c">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-weight: bold;">6.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-weight: bold;">Indemnity.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z91f899bd790c474bbc55f65174fd091e">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">6.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Survival of Representations and Warranties</u>. The representations and warranties of Hemispherian under Section 4 of this Agreement shall survive for a period of five (5) years following the Asset Transfer Closing Date, except that
              representations and warranties of Hemispherian under Sections 4.1, 4.2, 4.3, 4.4 and 4.9 shall survive indefinitely, and those under Section 4.7 shall only apply until the Asset Transfer Closing Date.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z02b1ad9d15254b7dace0b54b53bded15">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">6.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>General</u>. Hemispherian shall defend, hold harmless and indemnify the Company, together with the senior management, directors, employees thereof, as applicable, (the &#8220;<font style="font-weight: bold;">Indemnified Persons</font>&#8221;) from
              and against, and shall pay and reimburse each of them for, any and all Indemnifiable Losses actually incurred or sustained by, or imposed upon, any of them to the extent based upon, arising out of or in connection with the following, subject
              to any limitations on liabilities set forth hereunder:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb81b8753306d4da18fa1d3ea6eae0461">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">6.2.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Any breach of any of the representations or warranties of Hemispherian contained in this Agreement;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb9fb31e918454083910c4dd98a2fbee3">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">6.2.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Any breach or non-fulfilment of Hemispherian in performing any covenant, undertaking, agreement or obligation pursuant to this Agreement;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf3bd93e0850b4d9f8820900b366f8a1c">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">6.2.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Any claims or Liabilities raised or imposed by any Third Party or Governmental Authority in relation to the Company&#8217;s right, title and interest in and to any of the Transferred Assets, the Company&#8217;s ability to use, commercialize or
              otherwise exploit the Transferred IP or obligations of payments or compensations in relation thereof, including without limitation, any claim raised by Hemispherian&#8217;s current or former employees, Affiliates, independent contractors, agents,
              consultants, service providers and their respective employees, all arising from Excluded Liabilities;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3b0b33f12048469da8d139e92dece68f">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">6.2.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Any claim by any Third Party that the Transferred Assets infringe, misappropriate, or otherwise violate the Intellectual Property or other rights of such Third Party, to the extent that such claim does not (i) directly relate to any
              technology, materials or manufacturing processes that are developed and controlled by BioLine; and (ii) arise directly from the gross negligence, violation of law or willful misconduct on the part of BioLine; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd7ceea4ddced42c3b366ea0e62cb1e39">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">6.2.5</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Any Excluded Liabilities, any Liabilities otherwise retained by Hemispherian under this Agreement, and claims or Liabilities raised or imposed by any Governmental Authority.</div>
          </td>
        </tr>

    </table>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">9</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3453f1c4c5d24b288d25d0577c36a9ff">

        <tr>
          <td style="width: 23.85pt; vertical-align: top;">6.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Procedure for Indemnification of Claims</u>.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb11fe8557f8a418b8191301b584af9b6">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">6.3.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>If an Indemnified Person receives notice of the assertion or commencement of an Action made, brought by or in conflict with any Person (&#8220;<font style="font-weight: bold;">Claim</font>&#8221;) against such Indemnified Person that the Indemnified
              Person has determined has given or would reasonably be expected to give rise to a right of indemnification under this Section 6, the Indemnified Person shall provide Hemispherian with written notice of the Claim at the earliest opportunity
              but in any event within ten (10) Business Days of receiving such Claim, indicating the nature of the Claim and the basis therefor and including all related documents;&#160;<font style="font-style: italic;">provided, however</font>, that any
              failure to give such reasonably prompt written notice shall only relieve Hemispherian of its indemnification obligations to the extent that Hemispherian actually forfeits rights or defenses by reason of such failure. Hemispherian shall have
              the right, at its option, to participate in and/or assume the defense of, at its own cost and by its counsel, any such Claim involving the asserted liability of the Indemnified Person;&#160;<font style="font-style: italic;">provided, however</font>,
              that Hemispherian shall not have the right to assume the defense of a Claim if Hemispherian and/or its Affiliate is also a party to such Claim and the Indemnified Person determines in good faith that joint representation would render the
              defense of the Indemnified Person ineffective.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z24de7495497b4e25830a74716226e495">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">6.3.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>If Hemispherian shall undertake to assume the defense of or settle any such asserted Claim, it shall promptly notify the Indemnified Person of its intention to do so, and the Indemnified Person shall agree to cooperate with Hemispherian
              and its counsel in the defense against, or settlement of, any such asserted liability; <font style="font-style: italic;">provided, however</font>, that Hemispherian shall not, as part of any settlement or other compromise, admit to liability
              for which Hemispherian is not fully indemnifying the Indemnified Person or agree to an injunction with respect to activities of any Indemnified Person without the written consent of the Indemnified Person. Notwithstanding an election by
              Hemispherian to assume the defense of any Claim as set forth above, such Indemnified Person shall have the right (at its own cost if Hemispherian has elected to assume such defense) to employ separate counsel and to participate in the defense
              of any Claim. All costs incurred by an Indemnified Person in connection with enforcement of its rights under Section 6.2 shall also be reimbursed by Hemispherian promptly after final determination that such Indemnified Person is entitled to
              indemnification by Hemispherian.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z527da7d2307e405a9fc29c4d97be3e37">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-weight: bold;">7.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-weight: bold;">Parties&#8217; Obligations.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z437ea181340447c8b62d69cb9904af25">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">7.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Further disclosure of Transferred Assets</u>. Hemispherian confirms that it has uploaded to the Virtual Data Room copies of all documents and materials in relation to the Transferred Assets in its possession or under its control as of
              the Effective Date, and agrees that the Company and BioLine shall be entitled to the review and use of such documents and materials as it deems appropriate in its conduct of business and/or in the performance of the clinical trial activities
              it contemplates undertaking. On the Effective Date, Hemispherian shall produce and deliver to the Company a read only memory disk which contains a copy of all the documents and materials uploaded by Hemispherian to the Virtual Data Room as of
              the date of this Agreement. Hemispherian shall, on an on-going basis, following the Asset Transfer Closing Date, (i) make its personnel available to the Company and BioLine to promptly address reasonable inquiries by the Company and BioLine
              regarding such documents and materials, including without limitation, questions relating to the existence, nature, content and disclosure of all related documentation; and (ii) identify any relevant additional, missing or newly available
              documentation related to the Transferred Assets and notify the Company and BioLine thereof. Hemispherian will promptly provide all documentation identified in (i) and (ii) to the Company and BioLine and agrees that all such documentation
              shall thereafter immediately become part of the Transferred Assets for the purposes of this Agreement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za23d44f0c4704a7688693ff30e25d6ca">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">7.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Delivery of Lead Compound</u>. Hemispherian shall promptly and in any event within 30 Business Days after the Asset Transfer Closing Date, deliver or arrange to have delivered to the Company the chemical and biological embodiments of
              the Lead Compound and the Secondary Compound with all related information and documentation (including without limitation, the properties, specifications, quantities, yields, packaging information of the Lead Compound). Should the Company
              exercise its rights pursuant to Section 10 to obtain rights to any of the Other Compounds, the terms of this section shall apply <font style="font-style: italic;">mutatis mutandis</font> to such compounds, it being clarified that the
              delivery date of the relevant information and materials shall be 30 Business Days after the execution of the applicable documentation pursuant to which the Company obtains the rights to such compounds.</div>
          </td>
        </tr>

    </table>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">10</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4bc6887631b74a279094dfa3451a6bbd">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">7.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Registered IP Transfer Formalities</u>. Hemispherian and the Company have agreed to the joint appointment of the patent firm of Dehns based in London, to serve as the agent for verifying the IP Transfer Documentation against Applicable
              Laws and for filing with the appropriate Governmental Authorities to register the title transfer of each Registered IP from the relevant Hemispherian entity to the Company in accordance with Section 8.3 (the &#8220;<font style="font-weight: bold;">IP




                Agent</font>&#8221;). Hemispherian shall, based on comments of the IP Agent and/or BioLine, (a) prepare and provide to the Company and BioLine, for their review, complete copies of prepared forms of all IP Transfer Documentation required to be
              executed or issued by the Company, as soon as practically possible and in any event within 30 calendar days from the Effective Date. Within ten (10) calendar days thereafter, Hemispherian and the Company shall place in escrow with the IP
              Agent all IP Transfer Documentation that is duly executed and/or issued by Hemispherian and the Company for the IP Agent&#8217;s verification on the sufficiency for filing, to register the title transfer, and timely attend to the correction or
              supplementation of any IP Transfer Documentation based on the IP Agent&#8217;s comments, if any. All costs and expenses incurred with respect to the registration of title transfer for the Registered IP (including any filing fees, costs, and
              expenses of recordals and applications, notary and legalization costs and professional fees relating to the services of the IP Agent) shall be paid for by Hemispherian.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4f4c0265c9e44ad8b3e037caecd651fd">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">7.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Disclosure of Infringements</u>. Hemispherian shall notify the Company in writing promptly upon learning of any infringement, misappropriation, or other violation by any Person of any Transferred IP or Regulatory Information, or any
              allegation that any Transferred IP or Regulatory Information infringes, misappropriates, or otherwise violates the rights of a third party.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z483e27a3ed314992a246ce93f70f2ac6">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-variant: small-caps; font-weight: bold;">8.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-weight: bold;">Asset Transfer Closing.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1e85252d52234d68accac65798ddaadf">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">8.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The obligations of the Company and Hemispherian to complete the transactions as contemplated hereunder (the &#8220;<font style="font-weight: bold;">Asset Transfer Closing</font>&#8221;) are subject to and conditional upon the satisfaction of the
              following closing conditions (&#8220;<font style="font-weight: bold;">Closing Conditions</font>&#8221;):</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z34c8d51f75b24796aec360f597bb06d9">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">8.1.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Accuracy of Representations</u>. Each of the representations and warranties of Hemispherian set forth in this Agreement shall be true, correct, and complete in all respects as of the date of this Agreement and as of the Asset Transfer
              Closing Date as if made on and as of the Asset Transfer Closing Date (or, if given as of a specific date, at and as of such date).</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf6dfdb89a192407fa6e956691c5f724d">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">8.1.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>No breach</u>. Hemispherian shall confirm in writing that there is no breach or non-fulfillment of any covenant, undertaking, agreement, or obligation to be performed by Hemispherian pursuant to this Agreement (the &#8220;<font style="font-weight: bold;">Compliance Confirmation</font>&#8221;).</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1b9af9de97b84be7963ec47233f843bf">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">8.1.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Registered IP</u>. The IP Transfer Documentation, duly executed, is placed by Hemispherian and the Company in escrow with the IP Agent in accordance with Section 7.3 and is confirmed by the IP Agent to be compliant with the Applicable
              Law and sufficient for filing with the relevant Governmental Authorities to register the title transfer of all Registered IP in all jurisdictions to the Company.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb1ca3df2eadb443ca45b619f3ebe215e">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">8.1.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Filing Instructions</u>. Hemispherian and the Company shall have delivered irrevocable written instructions to the IP Agent to immediately file the IP Transfer Documentation.</div>
          </td>
        </tr>

    </table>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">11</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf312564b3c4c4f9ea1faa14b62b41c41">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">8.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>On the Asset Transfer Closing Date, Hemispherian shall deliver to the Company the following:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z07e4f96d387a406ab93bd74896d5a28b">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">8.2.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The Registered IP Deliverables;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf7f4d80fa6944e618d88a7f3b7d88816">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">8.2.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Copies of all Transferred Know-How, Regulatory Information and a complete and detailed list of the Transferred Know-How and Regulatory Information as updated by Hemispherian, which shall automatically be deemed to be included as <u>Schedule




                3</u> of this Agreement, and copies of all the Business Information, it being understood that such delivery shall be made by providing the Company with the DVD ROM containing copies of all Transferred IP, Regulatory Information and Business
              Information;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2490acafa024454ab503c65b200f39bb">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">8.2.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The Compliance Confirmation; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z56b889531f1742038c5ce88a30182c9d">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">8.2.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The DVD ROM.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf0bec61601354d33b55cb6139363f51f">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">8.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Immediately following the Asset Transfer Closing Date, Hemispherian and the Company shall jointly instruct the IP Agent to immediately apply to the appropriate Governmental Authority to register the title transfer of such Registered IP
              into the name of the Company. Thereafter, Hemispherian shall use its best efforts to have the Company&#8217;s name registered as proprietor thereof as soon as possible by working with the IP Agent to actively follow up with and timely respond to
              any further enquiries, amendments, supplementation, and other requirements of the relevant Governmental Authorities. The Company shall provide such assistance as reasonably requested by Hemispherian to assist it in the fulfilment of its
              obligations under this Section 8.3, including without limitation, making such applications of the title transfer in its own name or jointly with Hemispherian if required by Applicable Laws. Hemispherian and the Company shall use its best
              efforts to complete the title transfer of all of the Registered IP on an expedited basis following the Asset Transfer Closing Date.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z23a53740af7f4a5790792b63b1f80ea4">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-weight: bold;">9.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-weight: bold;">Post-Closing.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze490ba8ed9b849638aa8dfbbd653820b">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">9.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>At the reasonable request of the Company after the Asset Transfer Closing, Hemispherian shall promptly execute and deliver such instruments and do and perform such acts and things as may be necessary or desirable for effecting the
              consummation of the transactions contemplated hereby and the assignment of the Transferred Assets, including without limitation, prompt execution, acknowledgment and recordation of other such papers, as necessary or desirable for fully
              perfecting and conveying to the Company the benefit of the transactions contemplated herein and for facilitating the approval by the relevant Governmental Authority.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc1dd065f504041c2b7bf9ede7acade59">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">9.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Hemispherian acknowledges and agrees that the Company may, from time to time, in its conduct and furtherance of the JV Business and during the expected development, registration and commercialization processes of the Compounds and/or other
              products, require additional clarification, information, documentation and other materials from Hemispherian in respect of the Transferred Assets. Hemispherian shall, on an on-going basis after the Asset Transfer Closing Date, cooperate with
              and respond promptly to the Company&#8217;s reasonable written requests and provide or procure to be provided to the Company all such additional clarification, information, documentation, and other materials. In addition, Hemispherian agrees that
              it shall, upon the Company&#8217;s reasonable request, after the Asset Transfer Closing, assist the Company in obtaining services provided by Third Parties, including without limitation the suppliers and service providers that were engaged by
              Hemispherian in relation to the production, supply, research and development, and regulatory matters, and with respect to any other aspect of the JV Business.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd9b0562b38f446208d4bea1e688a046f">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">9.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Hemispherian undertakes to forward and transfer to the Company as soon as practicable, any documents, information, communications, correspondence or payments which Hemispherian may receive after the Asset Transfer Closing Date in relation
              to the Transferred Assets and which should have properly been received by or addressed to the Company pursuant to the terms of this Agreement or the Joint Venture Agreement, and agrees that any payments so received by Hemispherian after the
              Asset Transfer Closing Date shall be held by it as agent of the Company.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9fd65f8fbc184934afbe1e9ca6ba81f8">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">9.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Hemispherian undertakes to forward and transfer to the Company as soon as practicable but in any event within six (6) months of the Asset Transfer Closing Date, all copies of documents issued by relevant Governmental Authorities or other
              documentary evidence demonstrating the approval of the regulatory file transfers in accordance with Section 7.3 then in its possession or control.</div>
          </td>
        </tr>

    </table>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">12</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z826caa89af4d443480f8da2d9adaff3c">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">9.5</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>On an asset-by-asset basis, prior to the date on which the application for registration of title transfer of any Registered IP to the Company is approved by the relevant Governmental Authority:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z14c26d5890f44c84bf6fbf8f950b0d49">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">9.5.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Hemispherian shall use its best efforts to maintain in force at the Company&#8217;s expense (or procure that there is maintained in force, including by renewing at the Company&#8217;s expense any Registered IP that may expire) each Registered IP, and
              shall not voluntarily amend, cancel, or surrender any Registered IP unless requested to do so in writing by the Company. Hemispherian shall promptly provide the Company with such information as the Company may reasonably request concerning
              the maintenance of the Registered IP until the application for registration of title transfer of the Registered IP is approved by the relevant Governmental Authority; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z05b5bef6f9b249d79f718c4f814880a6">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">9.5.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>To the extent the ownership of any Registered IP or any rights under any Registered IP is considered to remain with Hemispherian under Applicable Law in any jurisdiction notwithstanding the transfer, assignment and conveyance provided in
              Section 2, Hemispherian hereby grants to the Company an exclusive, royalty-free, perpetual, worldwide, irrevocable, freely transferrable and sublicensable license to use the Registered IP for any purpose. Such license shall come to effect
              from the Asset Transfer Closing Date until the date on which the recordal of transfer of ownership of the Registered IP to the Company is approved by the relevant Governmental Authority and duly registered and completed.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd77c9bb88b034bc6a816707e9666e9bb">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">9.5.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>If the registration of title transfer of any Registered IP is eventually disapproved by the Governmental Authority or fails to be duly completed for any reason, (i) Hemispherian shall immediately register or file the exclusive license
              under Section 9.5.2 with the Governmental Authority to the extent required under the Applicable Law; and (ii) Hemispherian shall hold such Registered IP in trust for the benefit of and registered in its name as nominee for the Company and
              Hemispherian shall act as a trustee and shall not transfer, assign, or otherwise dispose of such Registered IP without the prior written consent of the Company.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z89e36127d8434dc7aef27893c01434d4">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">9.6</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>To the extent any Transferred Assets has any Encumbrance on it on the Effective Date and/or the Asset Transfer Closing Date, without limiting Hemispherian&#8217;s other obligations hereunder, Hemispherian shall promptly seek, obtain, and record
              from its lenders or other Third Party the release of any Encumbrance that may exist on any of the Transferred Assets.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z27fd7d306fbb45f2852d8ea2828efad6">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">9.7</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The Company shall have full control, at their expenses, over the preparation, filing, prosecution, maintenance, and enforcement of the Transferred Assets. Hemispherian shall not, and shall ensure that its Affiliates shall not, institute or
              actively participate as an adverse party in, or otherwise provide material support to, any challenge of any Registered IP, including without limitation, contest the validity or enforceability of such Registered IP, in whole or in part, in any
              court, arbitration proceeding or tribunal, including the United States and European Patent and Trademark Offices.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2c222fdc33c74f02a7adfc91735c6e9f">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">9.8</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Hemispherian shall, at its expense, take the following actions:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7d75bec44a7d49dc94dd6b15efdaef00">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">9.8.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Promptly following the determination by the Board of Directors of the Company, which shall meet after the Asset Transfer Closing Date to determine which of the contracts listed in <u>Schedule 5</u> hereto shall be novated to the Company
              (the &#8220;<font style="font-weight: bold;">Transferred Contracts</font>&#8221;), Hemispherian shall novated the Transferred Contracts to the Company. Hemispherian will keep the Company updated regarding the progress of the novation of the Transferred
              Contracts, and the parties will cooperate in good faith to complete such novation as expeditiously as possible; and</div>
          </td>
        </tr>

    </table>
    <br>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb3208550138e401399b393ae5f1fd6b6">

        <tr>
          <td style="width: 39pt;"><br>
          </td>
          <td style="width: 34.35pt; vertical-align: top;">9.8.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Immediately following the Asset Transfer Closing Date, Hemispherian will take all steps necessary to transfer the IND for the Lead Compound to the Company, including executing any required documents with the US FDA.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9256761e76b342cdad68b46319e4abfe">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">9.9</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>In addition, immediately following the Asset Transfer Closing Date, the parties will finalize the terms of a side letter pursuant to which (i) Hemispherian will transfer to the Company any existing inventory of the Lead Compound and
              ingredients therefor in its possession or under its control; and (ii) Hemispherian will place an order with [***] for an agreed quantity of GLIX1 to be supplied directly to the Company at the Company&#8217;s expense.</div>
          </td>
        </tr>

    </table>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">13</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb92b09cdd09e485b82580a6e80ececaf">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-weight: bold;">10.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">Compound Selection Provisions and Related Obligations.</font> The following arrangements shall apply to and govern the Company&#8217;s rights to the Secondary Compound and the Company&#8217;s option to obtain rights to
              the Other Compounds.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z60f69421a83b429e8f081b918684c265">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">10.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Secondary Compound</u>. At any time during a period of 60 months commencing from the effective date that the Secondary Compound Restricted Data is transferred to the Company in accordance with the terms of Section 10.3 below, the
              Company&#8217;s Board of Directors will determine whether the Secondary Compound shall remain owned by and subject to the development activities of the Company. If the Company&#8217;s Board of Directors determines that the Secondary Compound <font style="font-style: italic;">shall remain</font> owned by and subject to the development activities of the Company, the terms and conditions of this Agreement shall continue to apply thereto. However, if the Company&#8217;s Board of Directors
              determines that the Secondary Compound <font style="font-style: italic;">shall</font>&#160;<font style="font-style: italic;">not</font> remain owned by and thus not subject to the development activities of the Company, it shall advise
              Hemispherian in writing thereof and the following provisions will apply: (i) the Company shall transfer the Secondary Compound back to Hemispherian, and (ii) the Company shall have no further development obligations with respect thereto; and
              (iii) Hemispherian shall have the right to continue to research, develop and commercialize such compounds, subject to the ROFR arrangement set out in <u>Appendix A</u>, which shall apply to the Secondary Compound <font style="font-style: italic;">mutatis mutandis</font>.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9697452f47c842d3ac5593380ae40043">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">10.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Other Compounds</u>. Hemispherian hereby agrees that the Company shall have an exclusive option to terminate the License Back with respect to any or all of the Other Compounds (the &#8220;<font style="font-weight: bold;">Option</font>&#8221;)
              during a period of 48 months commencing from the Asset Transfer Closing Date for those Other Compounds existing at such time, it being understood that such 48 month period will commence on an Other Compound-by-Other Compound basis as any new
              Other Compound arises and notice thereof is provided to the Company (the &#8220;<font style="font-weight: bold;">Option Period</font>&#8221;). At any time during the Option Period, the Company may provide written notice to Hemispherian that it is
              exercising the Option to terminate the License Back to any specific one of the Other Compounds (the &#8220;<font style="font-weight: bold;">Selection Notice</font>&#8221;). The Company may issue multiple Selection Notices throughout the Option Period to
              reflect the possibility that the License Back may be terminated with respect to certain compounds at different times. In the event that the Company issues a Selection Notice, (i) the License Back to the Other Compound specified therein shall
              terminate immediately; and (ii) the Company shall pay to Hemispherian the actual documented research and development costs specifically related to the selected Other Compound(s) in respect of which the License Back has been terminated
              incurred by Hemispherian (as shown by payment records) plus [***]%. Any of the Other Compounds which are not selected as aforesaid during the Option Period shall be released from the Option and Hemispherian shall have the right to continue to
              research, develop and commercialize such compounds, subject to the ROFR arrangement set out in <u>Appendix A</u>.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z01c4c6c851d4417198e59de6521b0786">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">10.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Provisions related to Secondary Compound Restricted Data</u>. The Parties acknowledge that Hemispherian is party to an ongoing research project relating to the Secondary Compound which is supported by funding from the Research Council
              of Norway (the &#8220;<font style="font-weight: bold;">RCN</font>&#8221;) which is scheduled for completion by December 31, 2025 (the &#8220;<font style="font-weight: bold;">Project</font>&#8221;). Hemispherian undertakes to provide written notice to the Company
              upon completion of the Project and, during the following 30 days, Hemispherian will upload into a virtual data room all Secondary Compound Restricted Data in its possession or under its control. Hemispherian will make its personnel available
              to the Company to promptly address reasonable inquiries by the Company regarding such data, and identify and provide copies of any relevant additional, missing or newly available documentation &#8211; which shall likewise be uploaded promptly to
              the virtual data room. In parallel, promptly following completion of the Project, Hemispherian shall apply to the RCN for written approval to transfer the Secondary Compound Restricted Data to the Company. If the RCN <font style="font-style: italic;">approves</font> the transfer, Hemispherian undertakes to promptly take all necessary steps to transfer and assign the Secondary Compound Restricted Data to the Company, for no further consideration. If the RCN <font style="font-style: italic;">denies</font> the transfer, Hemispherian shall neither transfer nor grant rights to the Secondary Compound Restricted Data to any third party during the three-year period following Project completion (the &#8220;<font style="font-weight: bold;">Project Tail Period</font>&#8221;). At the end of the Project Tail Period, Hemispherian undertakes to promptly take all necessary steps to transfer and assign the Secondary Compound Restricted Data to the Company, for
              no further consideration. In addition to the foregoing, and for the purpose of clarity, Hemispherian shall neither transfer nor grant rights to the Secondary Compound Restricted Data to any third party commencing as of the Asset Transfer
              Closing Date. Upon the transfer of the Secondary Compound Restricted Data to the Company (whether following receipt of RCN approval or the end of the Project Tail Period), (i) the definition of &#8220;Transferred Know-How&#8221; shall be automatically
              read to <font style="font-style: italic;">include</font> Secondary Compound Restricted Data, and (ii) all applicable provisions in this Agreement that apply to the Transferred Assets, including the Transferred Know-How, shall henceforth be
              read to reflect the inclusion of the Secondary Compound Restricted Data within the relevant definitions.</div>
          </td>
        </tr>

    </table>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">14</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0fe5a723b8714eff9b27d5ae088d4e0f">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-weight: bold;">11.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">Transfer upon Cessation of Operations</font>. If (a) the Company (i) ceases or suspends operations for a period of [***] ([***]) consecutive months during the [***] year of the Company&#8217;s operations due to
              insufficient financial resources, (ii) ceases or suspends operations for a period of [***] ([***]) consecutive months during the [***] year of the Company&#8217;s operations due to insufficient financial resources, or (iii)&#160;ceases or suspends
              operations for a period of [***] ([***]) consecutive months of the Company&#8217;s operations due to insufficient financial resources any time after that and provided that no third-party investor (other than BioLine) has invested in the Company at
              the applicable time, or (ii) initiates a Liquidation (with the meaning provided in the Joint Venture Agreement) process; or (b) BioLine does not invest the total Threshold Amount (as defined in Section 4.1 of the Joint Venture Agreement),
              either Hemispherian or BioLine may terminate this Agreement by providing written notice to the other party. In such event, the Company shall assign to Hemispherian or to another entity or person as directed by Hemispherian all rights
              previously transferred to it by Hemispherian related to any and all Transferred Assets, and the Company shall have no further right to engage in the development, clinical evaluation and commercialization of the Transferred Assets or products
              based on them. The Company hereby appoints and designates Hemispherian as its true and lawful attorney-in-fact with specific powers to represent the Company to sign, acknowledge, swear to, deliver, file or record, at the appropriate public
              offices or private entities, any and all documents, certificates, and instruments necessary to proceed with the transfer of rights, title, and interest of the Transferred Assets as provided herein.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze4affa188e2c404eb1f441ae4b225e82">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-weight: bold;">12.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">Governing Law and Dispute Resolution.</font></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6484f1fa41ac4121aaa65658f8ad8e79">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">12.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Governing Law</u>. This Agreement is governed by and shall be construed in accordance with the laws of England and Wales, without reference to principles of conflicts of law that would cause the application of the laws of any other
              jurisdiction.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd4c456b768984f74a16c42f102ffff5e">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">12.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Disputes</u>. All disputes arising out of or in connection with this Agreement, including any question regarding its existence, validity, or termination (&#8220;<font style="font-weight: bold;">Dispute</font>&#8221;), shall be submitted to the
              decision of the chief executive officer of the Company and of Hemispherian, who shall make their best efforts to settle such matters amicably through good faith discussions In the event that the chief executive officers are unable to reach an
              agreement with respect to the Dispute within 15 days after the Dispute was submitted to them, the Dispute shall be submitted to the decision of (i) the chairperson of the Company and (ii) the chairperson of Hemispherian (collectively, the &#8220;<font style="font-weight: bold;">Designated Chairpersons</font>&#8221;), who shall make their best efforts to settle such matters amicably through good faith discussions.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z156e0e4625714e39935bcbabfe83ddab">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 21pt; vertical-align: top;">12.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Arbitration</u>. In the event that the Designated Chairpersons fail to reach an agreement with respect to the Dispute within 15 days after the Dispute was submitted to them, the Dispute may be referred by either Party to and finally
              resolved by arbitration administered by the International Chamber of Commerce (&#8220;<font style="font-weight: bold;">ICC</font>&#8221;) in accordance with the International Arbitration Rules for expedited arbitration then in force (the &#8220;<font style="font-weight: bold;">Rules</font>&#8221;), which rules are deemed to be incorporated by reference in this section, and as modified by the following provisions of this section: (i) the law governing this section shall be the laws of England
              and Wales; (ii) the seat of arbitration shall be Geneva, Switzerland; (iii) the arbitral tribunal shall consist of one arbitrator, unless the Parties cannot reach agreement on the identity of such arbitrator within 30 days of the matter being
              referred to arbitration, in which case the tribunal shall consist of three arbitrators who will be selected in accordance with the Rules; (iv) the language of the arbitration shall be English; (v) judgment upon any award and/or order may be
              entered in any court having jurisdiction thereof; and (vi) when a Dispute occurs and is subject to arbitration under this section, except for the matters subject to such Dispute, the Parties shall continue to exercise, perform, and fulfill
              their respective rights, duties, and obligations, as the case may be, under and in accordance with the provisions of this Agreement. The foregoing arrangements shall not derogate from a Party&#8217;s right to seek injunctive relief from a court of
              competent jurisdiction.</div>
          </td>
        </tr>

    </table>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">15</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z223517940d7b424e92956ec4c5957c15">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-variant: small-caps; font-weight: bold;">13.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">Miscellaneous.</font> This Agreement together with its Schedules, Addenda, Appendices, exhibits, and referenced documents constitute the entire agreement between the Parties regarding the subject matter
              hereof and supersedes any and all other agreements between the Parties regarding the subject matter hereof. In the event of any conflict or inconsistency between the terms of this Agreement and any referenced document, the terms of this
              Agreement shall govern, unless expressly stated otherwise in any such ancillary agreement. Except as expressly set forth herein, this Agreement may not be modified or amended except in writing executed by all Parties. If any part of this
              Agreement shall be invalid or unenforceable, such part shall be interpreted to give the maximum force possible to such terms as possible under Applicable Law, and such invalidity or unenforceability shall not affect the validity or
              enforceability of any other part or provision of this Agreement. The terms of this Agreement are not intended to be enforceable by any Person who is not a party to this Agreement, provided that BioLine is hereby designated as a third party
              beneficiary under this Agreement and BioLine shall have the right to enforce the terms and conditions of this Agreement and determine whether any of the closing conditions are satisfied as if it were a direct party to this Agreement where it
              is expressly named. Nothing in this Agreement shall be deemed to constitute a partnership among any of the Parties hereto. This Agreement is prepared in English which shall be the language of interaction for all purposes between the Parties.
              This Agreement may be executed simultaneously in two or more counterparts, each of which shall be deemed an original.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5f021f4344ee4c44b968efbbf81fdbc3">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-variant: small-caps; font-weight: bold;">14.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">Schedules.</font> The following schedules, attached hereto, form an integral part of this Agreement:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-variant: small-caps;">Schedule 1:</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-variant: small-caps;">Other Compounds</font></div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-variant: small-caps;">Schedule 2:</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-variant: small-caps;">Transferred Patents</font></div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-variant: small-caps;">Schedule 3:</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-variant: small-caps;">Transferred Trademarks</font></div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-variant: small-caps;">Schedule 4:</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-variant: small-caps;">Transferred Know-How and Regulatory Information</font></div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-variant: small-caps;">Schedule 5:</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-variant: small-caps;">List of Contracts subject to Novation</font></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-variant: small-caps;">Appendix A:</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-variant: small-caps;">License Back</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">16</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">IN WITNESS WHEREOF, the parties hereto have executed this Asset Transfer Agreement as of the Effective Date.</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" style="font-family: Arial; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z82f4aaee0e5346ae9487ae1d2942857a">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman'; font-weight: bold;">Tetragon Biosciences Ltd.</div>
              <div style="line-height: 1.25; font-family: 'Times New Roman';">&#160;</div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman'; font-weight: bold;">Hemispherian AS</div>
              <div style="line-height: 1.25; font-family: 'Times New Roman';">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman';">Signature: <u>/s/ Philip Serlin</u></div>
              <div style="line-height: 1.25; font-family: 'Times New Roman';">&#160;</div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman';">Printed Name: Philip Serlin</div>
              <div style="line-height: 1.25; font-family: 'Times New Roman';">&#160;</div>
              <div style="line-height: 1.25; font-family: 'Times New Roman';">Title: Chairman of the Board</div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman';">Signature: <u>/s/ Paul Lelieveld</u></div>
              <div style="line-height: 1.25; font-family: 'Times New Roman';">&#160;</div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman';">Printed Name: Paul Lelieveld</div>
              <div style="line-height: 1.25; font-family: 'Times New Roman';">&#160;</div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman';">Title: Chairman of the Board</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">By signing below, BioLineRx Ltd. shall be bound by and may enforce Sections 7.1, 7.3, 11 and 13.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z95bce5c9485840238a939b78f16f01fd">

          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-weight: bold;">BioLineRx Ltd.</div>
              <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Signature: <u>/s/ Philip Serlin</u></div>
              <div style="text-align: justify; line-height: 1.25;">Printed Name:<font style="font-style: italic;">&#160;</font>Philip Serlin</div>
              <div style="text-align: justify; line-height: 1.25;">Title: Chief Executive Officer</div>
            </td>
          </tr>

      </table>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">17</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Schedule 1</div>
    <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Other Compounds</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-variant: small-caps;">[***]</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">18</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Schedule 2</div>
    <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Transferred Patents</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-variant: small-caps;">[***]</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">19</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Schedule 3</div>
    <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Transferred Trademarks</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-variant: small-caps;">[***]</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">20</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Schedule 4</div>
    <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Transferred Know-How and Regulatory Information</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-variant: small-caps;">[***]</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">21</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Schedule 5</div>
    <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">List of Contracts subject to Novation</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-variant: small-caps;">[***]</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">22</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <br>
    <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Appendix A</div>
    <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">License Back</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">The License.</font></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z81e288a6e15a4ab08e55618930a8b0dc">

        <tr>
          <td style="width: 35.45pt; vertical-align: top;">1.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The Company hereby grants to Hemispherian (i) a world-wide, exclusive, non-transferable and non-sublicensable right and license under the Company&#8217;s rights in the Transferred Patents to use or have used, make or have made, develop or have
              developed, adjust, modify, enhance, create derivative works, manufacture or have manufactured, and commercialize Other Compounds; and (ii) a world-wide, non-exclusive, non-transferable and non-sublicensable right and license under the
              Company&#8217;s rights in the Transferred Patents to engage in research and development activities within the scope of and during the period of the Project with respect to the Secondary Compound (the &#8220;<font style="font-weight: bold;">License</font>&#160;<font style="font-weight: bold;">Back</font>&#8221;). Any and all activities performed by Hemispherian under the License Back shall be at Hemispherian&#8217;s sole costs and expenses, and Hemispherian shall assume and bear all liabilities in connection
              therewith.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd532566d4cba488583bc45b2ee678147">

        <tr>
          <td style="width: 35.45pt; vertical-align: top;">1.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The License Back granted under <font style="font-weight: bold;">Section 1.1(i)</font> above may be terminated as provided in Section 10.2 of the Agreement on an Other Compound-by-Other Compound basis. In the event that termination does
              not occur within the time period specified in Section 10.2 of the Agreement (the &#8220;Time Period&#8221;), the License Back shall become perpetual, irrevocable, sublicensable, transferrable, and fully paid with respect to each such Other Compound, <font style="font-style: italic;">subject, however</font>, to the ROFR set out in Section 1.3 below. The License Back granted under <font style="font-weight: bold;">Section 1.1(ii)</font> above shall terminate automatically upon the transfer of
              the Secondary Compound Restricted Data to the Company pursuant to the terms of Section 10.3 of the Agreement. In the event that the Company&#8217;s Board of Directors determines that the Secondary Compound <font style="font-style: italic;">shall</font>&#160;<font style="font-style: italic;">not</font> remain owned by the Company as contemplated in Section 10.1 of the Agreement, the Company will once again grant to Hemispherian the License Back contemplated in Section 1.1(ii) above, it being
              clarified that (a) such license shall be expanded to include the right to engage in commercialization activities with respect to the Secondary Compound, and (b) the ROFR arrangement set out in <u>Section 1.3 below </u>shall apply to the
              Secondary Compound <font style="font-style: italic;">mutatis mutandis</font>.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z489abd846f90412fa610031417748317">

        <tr>
          <td style="width: 35.45pt; vertical-align: top;">1.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Right of First Refusal</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb0023f4d78d94d54b16e8cbd3718bdde">

        <tr>
          <td style="width: 7.65pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top;">1.3.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>ROFR Arrangement with respect to the <font style="font-weight: bold;">Other Compounds</font>: In the event that Hemispherian receives a <font style="font-style: italic;">bona fide</font> written offer from a third party (the &#8220;Offer&#8221;) to
              purchase and/or license and/or acquire rights to the Other Compound (the &#8220;Proposed Transaction&#8221;) in respect of which the Company did not terminate or revoke the License Back within the Time Period at any time between the expiration of the
              Time Period and [***] months (the &#8220;ROFR Period&#8221;), and Hemispherian desires to accept such Offer, Hemispherian shall first provide written notice (the &#8220;Notice&#8221;) to the Company of the material terms and conditions of the Offer, including the
              identity of the third party. The Company shall have [***]<font style="font-variant: small-caps;">&#160;</font>calendar days following receipt of the Notice to notify Hemispherian in writing whether it elects to proceed with the Proposed
              Transaction on the same terms and conditions as set forth in the Offer.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdcdc03747189439b85df5d64a316de24">

        <tr>
          <td style="width: 7.65pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top;">1.3.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>ROFR Arrangement with respect to the <font style="font-weight: bold;">Secondary Compound</font>: In the event that Hemispherian receives a <font style="font-style: italic;">bona fide</font> written offer from a third party (the &#8220;Offer&#8221;)
              to purchase and/or license and/or acquire rights to the Secondary Compound (the &#8220;Proposed Transaction&#8221;) after the time that the Company&#8217;s Board of Directors determines that the Secondary Compound <font style="font-style: italic;">shall</font>&#160;<font style="font-style: italic;">not</font> remain owned by the Company as contemplated in Section 10.1 of the Agreement and 72 months thereafter (the &#8220;ROFR Period&#8221;), and Hemispherian desires to accept such Offer, Hemispherian shall first
              provide written notice (the &#8220;Notice&#8221;) to the Company of the material terms and conditions of the Offer, including the identity of the third party. The Company shall have <font style="font-variant: small-caps;">[***] </font>calendar days
              following receipt of the Notice to notify Hemispherian in writing whether it elects to proceed with the Proposed Transaction on the same terms and conditions as set forth in the Offer.</div>
          </td>
        </tr>

    </table>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">23</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3b9b9c20fc1b4e1cbb038ffa3fe9ec59">

        <tr>
          <td style="width: 35.45pt; vertical-align: top;">1.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>If the Company timely elects to exercise its right, the Parties shall proceed in good faith to consummate the Proposed Transaction on such terms. If the Company does not timely elect to exercise its right or notifies Hemispherian that it
              does not wish to do so, Hemispherian may consummate the Proposed Transaction with the third party on terms no more favorable to the third party than those set forth in the Notice. If Hemispherian does not consummate the transaction with the
              third party within <font style="font-variant: small-caps;">[***] </font>calendar days after the expiration of the Company&#8217;s response period, the right of first refusal shall again apply to any subsequent proposed transaction.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z789857394d724ff2ba74e4e4d177ecac">

        <tr>
          <td style="width: 35.45pt; vertical-align: top;">1.5</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>This right of first refusal shall survive and remain in effect until the expiration of the ROFR Period on an Other Compound-by-Other Compound basis as per Section 1.3.1 above, or until the end of the ROFR Period as per Section 1.3.2 above,
              as applicable.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Indemnification.</font></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0c8aefdbbc544e5abf6f795afad12130">

        <tr>
          <td style="width: 35.45pt; vertical-align: top;">2.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>In addition to the Indemnities provided in Section 6 of the Assets Transfer Agreement, in connection with the License Back provided in this Appendix, Hemispherian shall indemnify, defend and hold harmless the Company, its officers, agents
              and employees (collectively, the &#8220;Indemnified Parties&#8221;), from and against any and all liability, loss, damage, action, claim or expense suffered or incurred by the Indemnified Parties which results from or arises out of third party claims in
              connection with: (a) the development, use, manufacture, promotion, sale, distribution or other disposition of any Other Compounds and/or Secondary Compound by Hemispherian, its Affiliates, assignees, vendors or other third parties, for
              personal injury, including death, or property damage arising from any of the foregoing; (b) any actual or alleged infringement or misappropriation by Hemispherian, or any person developing an Other Compound and/or the Secondary Compound by or
              through Hemispherian, of any intellectual property or other right of Company or any person or entity; (c) any product liability or other claim of any kind related to the use by a third party of an Other Compound and/or the Secondary Compound
              that was developed, manufactured, sold, distributed or otherwise disposed by Hemispherian; (d) clinical trials or studies conducted by or on behalf of Hemispherian relating to any Other Compound and/or the Secondary Compound, including,
              without limitation, any claim by or on behalf of a human subject of any such clinical trial or study, any claim arising from the procedures specified in any protocol used in any such clinical trial or study, any claim of deviation, authorized
              or unauthorized, from the protocols of any such clinical trial or study, any claim resulting from or arising out of the manufacture or quality control by a third party of any substance administered in any clinical trial or study; or (e)
              failure to comply with all prevailing laws, rules and regulations pertaining to the development, testing, manufacture, marketing and import or export of any Other Compound and/or Secondary Compound.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
  </div>
  <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">24</font>
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exhibit_10-2.htm
<DESCRIPTION>COLLABORATION AND SHAREHOLDERS AGREEMENT, DATED AS OF SEPTEMBER 29, 2025, BETWEEN BIOLINERX LTD. AND HEMISPHERIAN AS
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 25.8.1.5328
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div>
    <div style="text-align: right;"><u><font style="font-weight: bold;">Exhibit 10.2</font></u></div>
    <div><br>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Certain confidential information contained in this document, marked by brackets and asterisk ([***]), has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K, because
      the Company customarily and actually treats such information as private or confidential and the omitted information is not material.</div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-variant: small-caps; font-weight: bold;"><u>Collaboration and Shareholders Agreement</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This Collaboration and Shareholders Agreement (the &#8220;<font style="font-weight: bold;">Agreement</font>&#8221;) is made and entered into as of September 29, 2025 (the &#8220;<font style="font-weight: bold;">Effective Date</font>&#8221;), by and among (a) Tetragon Biosciences Ltd., a company incorporated under the laws of the State of Israel (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;) and whose registered address is 2
      HaMa&#8217;ayan Street,&#160; Modiin 7177871, Israel, (b) BioLineRx Ltd., a publicly traded company incorporated under the laws of the State of Israel (&#8220;<font style="font-weight: bold;">BioLine</font>&#8221;) (NASDAQ:BLRX) and whose registered address is 2 HaMa&#8217;ayan
      Street, Modiin 7177871, Israel, and (c) Hemispherian AS, a private company incorporated under the laws of the Kingdom of Norway and whose registered address is L&#248;renveien 73A, 0585 Oslo, Norway (&#8220;<font style="font-weight: bold;">Hemispherian</font>&#8221;,
      and each of Hemispherian and BioLine, a &#8220;<font style="font-weight: bold;">Shareholder</font>&#8221; and collectively, the &#8220;<font style="font-weight: bold;">Shareholders</font>&#8221;). The Company and the Shareholders are referred to collectively herein as the &#8220;<font style="font-weight: bold;">Parties</font>&#8221; and separately as a &#8220;<font style="font-weight: bold;">Party</font>&#8221;.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold;">WHEREAS</font>, BioLine and Hemispherian have entered into that certain letter of intent dated as of June 15, 2025 (the &#8220;<font style="font-weight: bold;">LOI</font>&#8221;), setting forth high-level terms of the Collaboration (as defined below);</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold;">WHEREAS</font>, in connection with the Collaboration, certain Parties have entered into or will enter into certain related agreements, including
      the Asset Transfer Agreement (collectively, the &#8220;<font style="font-weight: bold;">Related Agreements</font>&#8221;); and</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold;">WHEREAS</font>, the Parties desire to enter into this Agreement to set forth their rights and obligations as Shareholders of the Company and
      certain other terms and conditions that will govern the Collaboration, and the operations and management of the Company.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold;">NOW, THEREFORE</font>, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration,
      the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z6db90344a18942fc8a31fd1ee5d0dd7b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;"><u>Interpretation; Definitions</u></font><u>.</u></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zf44070334fc144308dacb12aa0a2e546" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">1.1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The Recitals, Schedules, and Exhibits hereto constitute an integral part hereof.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zde18dd4f8db74b308582ee2063f72a8c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">1.2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The headings of the sections and subsections of this Agreement are for convenience of reference only and are not to be considered in construing this Agreement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z32e01485d3f44f44b86c949a6f8bafb0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">1.3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>In this Agreement, unless the context otherwise requires:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z524e8bd569c4422b912c3c29e4b4e129" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 127.55pt;"><br>
          </td>
          <td style="width: 70.9pt; vertical-align: top;">1.3.1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Affiliate</font>&#8221; means, with respect to any Person, any other Person, directly or indirectly, through one or more intermediary Persons, affiliated with such Person, or Controlling, Controlled by, or under
              common Control with such Person.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zb09981ef0cac4ad5b4dd039319b6b34a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 127.55pt;"><br>
          </td>
          <td style="width: 70.9pt; vertical-align: top;">1.3.2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Applicable Law</font>&#8221; means any applicable federal, state, national, provincial, territorial, foreign or local law, common law, statute, ordinance, rule, regulation, code, circular, or order of any
              Governmental Authority, including the jurisdiction of incorporation of the Company, and including any rules promulgated by a stock exchange or regulatory body.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z6cb30a6d09314c55ba2561056cbb800d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 127.55pt;"><br>
          </td>
          <td style="width: 70.9pt; vertical-align: top;">1.3.3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Asset Transfer Agreement</font>&#8221; means that certain Asset Transfer Agreement by and between Hemispherian and the Company, dated on or around the date of this Agreement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z6c0b8fce671247f8a7bfb983d4d16f5d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 127.55pt;"><br>
          </td>
          <td style="width: 70.9pt; vertical-align: top;">1.3.4.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Budget</font>&#8221; means the initial mutually agreed-upon budget attached hereto as <u>Schedule </u><u>1.3.4</u>, as may be updated from time to time by the Company&#8217;s Board.</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z4dea256a82834c01833d72ba7deedf59" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 127.55pt;"><br>
          </td>
          <td style="width: 70.9pt; vertical-align: top;">1.3.5.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Business Day</font>&#8221; means any day other than a Friday, Saturday, Sunday, or other day on which commercial banks in Norway or the State of Israel are required or authorized by Applicable Law to be closed,
              at any time between 9:00 a.m. and 5:00 p.m. in the time zone of the relevant jurisdiction.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z066b0aea07ef42889c46f91918b3d2b9" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 127.55pt;"><br>
          </td>
          <td style="width: 70.9pt; vertical-align: top;">1.3.6.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Confidential Information</font>&#8221; means all non-public, confidential or proprietary information of a Party, whether in oral, written, electronic or other form or media, whether or not such information is
              marked, designated or otherwise identified as &#8220;confidential&#8221; and regardless of the manner in which it is disclosed, including, without limitation, all information concerning the Compounds, Products, past, present and future business affairs,
              products, services, research and development, designs, methods, processes, technical data, engineering information, financial information, procurement requirements, customer lists, business forecasts, sales and merchandising, and marketing
              plans, in each case to the extent non-public, confidential or proprietary.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z6c8e147554664c118b854f4e31ece713" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 127.55pt;"><br>
          </td>
          <td style="width: 70.9pt; vertical-align: top;">1.3.7.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Control</font>&#8221; means the power to direct the management and policies of the Person (other than an individual) in question, whether through the ownership of voting securities, appointment of members to its
              board or the chief executive officer, by contract or otherwise, and &#8220;<font style="font-weight: bold;">Controlling</font>&#8221; and &#8220;<font style="font-weight: bold;">Controlled</font>&#8221; have corresponding meanings.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z13dddae4a4d44ad3aea069a062b76163" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 127.55pt;"><br>
          </td>
          <td style="width: 70.9pt; vertical-align: top;">1.3.8.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Convertible Securities</font>&#8221; shall mean any evidence of indebtedness, shares or other securities directly or indirectly convertible into or exchangeable for Share Capital, but excluding Options.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z6608878f46144489acd641890511acb8" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 127.55pt;"><br>
          </td>
          <td style="width: 70.9pt; vertical-align: top;">1.3.9.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Development Plan</font>&#8221; means the initial development plan attached hereto as <u>Schedule </u><u>1.3.9</u>, as may be updated from time to time by the Company&#8217;s Board.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z1ccab40cd0a04465a2c36c3c89c38850" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 127.55pt;"><br>
          </td>
          <td style="width: 70.9pt; vertical-align: top;">1.3.10.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Governmental Authority</font>&#8221; means any central, state, federal, city, municipal, foreign or local governmental or quasi-governmental authority of any nature (including any governmental agency, branch,
              bureau, department or other entity and any court or other tribunal), any authority, regulator, body or other organization exercising, or entitled to exercise, any administrative, executive, judicial, legislative, police, regulatory or taxing
              authority or power of any nature, and any official of any of the foregoing in any jurisdiction of the world (including the jurisdiction of the Company&#8217;s incorporation).</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="za2545f1f373a4faaae4858d701488613" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 127.55pt;"><br>
          </td>
          <td style="width: 70.9pt; vertical-align: top;">1.3.11.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">IPO</font>&#8221; means the consummation of an initial public offering of the Company&#8217;s securities, pursuant to a registration statement under the Securities Act (as such term is defined below), or similar
              securities laws of another jurisdiction, or (b) a SPAC Transaction.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zea71d15dfd5943779905bb31d92f6391" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 127.55pt;"><br>
          </td>
          <td style="width: 70.9pt; vertical-align: top;">1.3.12.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Liquidation</font>&#8221; means any dissolution, liquidation, bankruptcy, or reorganization or winding-up of the Company.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z05b913ac51e346809a9f8d1ab83eb289" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 127.55pt;"><br>
          </td>
          <td style="width: 70.9pt; vertical-align: top;">1.3.13.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">M&amp;A Event</font>&#8221; means (i) a merger, consolidation, recapitalization, transfer, or similar event of the Company with or into another corporation in a single transaction or a series of related
              transactions as a result of which the shareholders of the Company immediately prior to such transaction do not hold a majority of the voting securities of the surviving entity,&#160; (ii) a sale or grant of an exclusive license for all or
              substantially all of the intellectual property rights of the Company (which has the same effect or economic impact as the disposition or sale of all or substantially all of the assets of the Company), or any other disposition of all or
              substantially all of the Company&#8217;s assets, or (iii) a sale of all or substantially all of the Share Capital of the Company to any person or entity (other than a reincorporation transaction whose sole purpose is the changing of the Company&#8217;s
              domicile).</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z77916a77e6e54ddebd7a461d5a04a58b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 127.55pt;"><br>
          </td>
          <td style="width: 70.9pt; vertical-align: top;">1.3.14.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Option</font>&#8221; shall mean rights, options or warrants to subscribe for, purchase or otherwise acquire Ordinary Shares or Convertible Securities, including any securities which by their terms convertible
              into or exchangeable for Ordinary Shares or options to purchase or rights to subscribe for such convertible or exchangeable securities.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zbe18dea9657c4be8895bc1fa4d9d21c4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 127.55pt;"><br>
          </td>
          <td style="width: 70.9pt; vertical-align: top;">1.3.15.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Ordinary Shares</font>&#8221; means Ordinary Shares of the Company, of no par value&#160; each.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zb37209389f784b80ba43846d814d6f71" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 127.55pt;"><br>
          </td>
          <td style="width: 70.9pt; vertical-align: top;">1.3.16.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Person</font>&#8221; means an individual, corporation, partnership, joint venture, trust, any other corporate entity and any unincorporated association or organization.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z0493cc1decc846eb873784b790735cf7" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 127.55pt;"><br>
          </td>
          <td style="width: 70.9pt; vertical-align: top;">1.3.17.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Qualified Financing</font>&#8221; means a financing whereby the Company issues shares of its Share Capital to a new third party investor, for a Company pre-money valuation of at least US$[***], resulting in
              gross cash proceeds to the Company of&#160; at least US$[***].</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z7e813e5fd99e48d6a202536fb44ef2b0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 127.55pt;"><br>
          </td>
          <td style="width: 70.9pt; vertical-align: top;">1.3.18.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">QIPO</font>&#8221; shall mean an IPO&#160;in which the Company receives aggregate net proceeds of at least US$[***] at a valuation of the Company which is at least US$[***].</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z3a77341d7b034c969f9f043df23bc95a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 127.55pt;"><br>
          </td>
          <td style="width: 70.9pt; vertical-align: top;">1.3.19.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Qualified M&amp;A</font>&#8221; means an M&amp;A Event in which the valuation of the Company is not less than US$[***].</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zc8bd31931c8747c4b7cf7a5894bcf60d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 127.55pt;"><br>
          </td>
          <td style="width: 70.9pt; vertical-align: top;">1.3.20.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Share Capital</font>&#8221; means the share capital of the Company, including, without limitation, the &#8220;<font style="font-weight: bold;">Ordinary Shares</font>&#8221; and the &#8220;<font style="font-weight: bold;">Preferred



                Shares</font>&#8221;, if any.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z402607bf83954bf9af751477c557288a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 127.55pt;"><br>
          </td>
          <td style="width: 70.9pt; vertical-align: top;">1.3.21.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">Securities Act</font>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z8328dda9fcd44dd1aee23cc84306297d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 127.55pt;"><br>
          </td>
          <td style="width: 70.9pt; vertical-align: top;">1.3.22.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">SPAC Transaction</font>&#8221; means a merger, consolidation, share exchange, share purchase or other business combination between (1) the shareholders of the Company, the Company and/or a wholly-owned
              subsidiary of the Company and (2) a publicly listed &#8220;special purpose acquisition company&#8221; (a &#8220;<font style="font-weight: bold;">SPAC</font>&#8221;) and/or its shareholders (or a subsidiary of the publicly listed company), in connection with which
              either (x) the Company becomes a publicly listed Company (or a subsidiary of a publicly listed company), or (y) the shareholders of the Company immediately prior to the closing of such merger, consolidation, share exchange, share purchase or
              other business combination hold or have the right, by virtue of their shareholdings in the Company, to acquire or to be issued, immediately following the closing of such merger, consolidation, share exchange, share purchase or other business
              combination, the majority shareholding in a publicly listed company that is the surviving entity of such merger, consolidation, share exchange, share purchase or other business combination.</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="zf924db7eb663488eb1849eedcb3a4e8a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;"><u>Purpose</u></font>.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z44c5b2fcb8164cfcbb13f6dff594f55f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">2.1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>In furtherance of the LOI, the Company has been formed to pursue the JV Business for the development, clinical evaluation and commercialization of products based on the Lead Compounds (as such terms are defined in the Asset Transfer
              Agreement) and other compounds as may be agreed by the Shareholders (the &#8220;<font style="font-weight: bold;">Compounds</font>&#8221;), and other products as may be developed by the Company, (the &#8220;<font style="font-weight: bold;">Products</font>&#8221;), as
              further detailed in this Agreement and the Related Agreements (as defined below (the &#8220;<font style="font-weight: bold;">Collaboration</font>&#8221;).</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zd8ae53e548914aa3a336289cffd50816" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">2.2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The Company shall adopt articles of association, and other customary incorporation documents to reflect the agreements set forth in this Agreement. These documents shall be in compliance with Applicable Law and shall be substantially in
              the form of Schedule 2.2 (the &#8220;<font style="font-weight: bold;">Articles of Association</font>&#8221;).</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z1b997df501224be0b605116cb4e3ff4b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;"><u>Shareholdings</u></font><u>.</u></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zed794e31bb27417fa8caf3333e410ed6" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">3.1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Shareholdings</u>. As of the Company&#8217;s incorporation, the Company&#8217;s Share Capital on an issued and outstanding basis shall be allocated as follows:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zb256953b5c0145a2a82e6402865c62bd" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 110.55pt;"><br>
          </td>
          <td style="width: 70.9pt; vertical-align: top;">3.1.1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Hemispherian shall hold 60% of the issued and outstanding Share Capital of the Company as of the date of its incorporation; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z21d00fe408d749849c8a8ca48bde5492" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 110.55pt;"><br>
          </td>
          <td style="width: 70.9pt; vertical-align: top;">3.1.2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>BioLine shall hold 40% of the issued and outstanding Share Capital of the Company as of the date of its incorporation&#160;(the &#8220;<font style="font-weight: bold;">BioLine Initial Percentage Holding</font>&#8221;).</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zfd101fa4828a475caf24e8af1cc9c496" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">4.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;"><u>Funding</u></font><u>.</u></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zb0be721d67cc44d98bd4e71bcb402eff" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">4.1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Initial Funding.</u>&#160;Except with the prior written consent of BioLine and except for the right of Hemispherian set forth in Section 4.3 below, no person or entity other than BioLine shall be permitted to invest in the Company, whether
              by way of equity, shareholder loans, debt, convertible instruments, or any other means. In consideration for receiving the BioLine Initial Percentage Holding, BioLine shall invest US$5,000,000 (the &#8220;<font style="font-weight: bold;">Threshold
                Amount</font>&#8221;) in the Company within thirty-six (36) months from the date of this Agreement in installments and based on the timing set forth in the Development Plan. The investment may take the form of equity, a shareholder loan, or any
              other form (provided, however, that any shareholders loan provided will ultimately be converted into equity and shall not be repaid in cash) approved by the Board. If BioLine does not invest the entire Threshold Amount within such period,
              BioLine will be granted an automatic one-time extension of six (6) additional months (together the &#8220;<font style="font-weight: bold;">Threshold Term</font>&#8221;), provided that the Development Plan is actively underway and the Shareholders have
              demonstrated continued good faith efforts to advance the Company&#8217;s activities. Once the total Threshold Amount has been provided to the Company by BioLine, BioLine shall have no further obligation to invest any additional funds in the
              Company. For the avoidance of doubt, the BioLine Initial Percentage Holding will not be increased on account of the investment of the Threshold Amount. In the event that BioLine does not invest the full Threshold Amount in the Company during
              the Threshold Term, Hemispherian shall have the right, at its sole discretion, to purchase, for nominal value, a pro-rata portion of the BioLine Initial Percentage Holding corresponding to the portion of the Threshold Amount not invested (the
              &#8220;<font style="font-weight: bold;">Hemispherian Repurchase Right</font>&#8221;). For example, if BioLine invests only US$2,500,000 of the Threshold Amount during the Threshold Term, Hemispherian shall be entitled to purchase from BioLine, for
              nominal value, fifty percent (50%) of the shares originally issued to BioLine as part of the BioLine Initial Percentage Holding. It is hereby clarified that the Hemispherian Repurchase Right shall also apply if the Agreement is terminated
              pursuant to Section 17 prior to BioLine investing the Threshold Amount in full, and in such case, Hemispherian shall have the right, at its sole discretion, to purchase, for nominal value, a pro-rata portion of the BioLine Initial Percentage
              Holding corresponding to the portion of the Threshold Amount not invested as of the date of termination.</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z2b5b1be13c40420b96dd4c748c367f7e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">4.2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Increase in Shareholding</u>. For each subsequent investment of US$1,000,000 by BioLine in the Company from time to time beyond the Threshold Amount, BioLine shall be entitled to receive an additional one percent (1%) of the equity in
              the Company, with a corresponding proportional reduction in Hemispherian&#8217;s shareholding. For illustrative purposes, if BioLine invests an additional US$10,000,000 beyond the Threshold Amount, the resulting shareholdings of BioLine and
              Hemispherian would each be fifty percent (50%) of the Company&#8217;s Share Capital on an issued and outstanding basis. This mechanism shall remain in effect until BioLine has invested an aggregate of US$30,000,000 beyond the Threshold Amount, at
              which point BioLine shall hold seventy percent (70%) of the Company&#8217;s share capital and Hemispherian shall hold thirty percent (30%) of the Company&#8217;s share capital.&#160; Notwithstanding anything to the contrary herein, BioLine&#8217;s aggregate
              holdings in the Company shall not exceed seventy percent (70%) of the Company&#8217;s Share Capital on an issued and outstanding basis as a result of additional cash investments by BioLine. For the avoidance of doubt, any investment by BioLine in
              the Company beyond the Threshold Amount may be made through equity investments, shareholder loans, or any other reasonable structure, as approved by the Board. For any investment amount that is not an exact multiple of US$1,000,000, the
              corresponding equity percentage to be issued to BioLine shall be calculated on a pro-rata, linear basis.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z9c8d60a47fac46fe92226396d0c90d9b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">4.3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Hemispherian Participation</u>. Notwithstanding anything to the contrary herein, should Hemispherian&#8217;s holdings fall below fifty percent (50%) of the Company&#8217;s Share Capital on an issued and outstanding basis (as a result of BioLine&#8217;s
              investment of the full Threshold Amount and an additional US$10,000,000 into the Company), Hemispherian shall have the right, but not the obligation, to invest in the Company on a <font style="font-style: italic;">pari passu</font> basis
              with BioLine or any other investor, solely to the extent necessary to preserve its existing shareholding up to a maximum of fifty percent (50%) of the Company&#8217;s Share Capital on an issued and outstanding basis. Any such investment by
              Hemispherian to be made pursuant to the terms of this Section 4.3, shall be made on the same terms and conditions as the relevant investment triggering this right. Notwithstanding anything to the contrary herein, prior to any investment in
              the Company that would result in Hemispherian&#8217;s shareholding falling below fifty percent (50%) of the Company&#8217;s Share Capital on an issued and outstanding basis, the Company shall provide Hemispherian with at least [***] days&#8217; prior written
              notice of such proposed investment. Hemispherian shall have [***] days from receipt of such notice to notify the Company in writing whether it elects to participate in such investment in order to maintain its shareholding at up to fifty
              percent (50%) of the Company&#8217;s Share Capital. If Hemispherian does not provide such written notice within the [***] day period, it shall be deemed to have irrevocably waived its right to invest with respect to such investment.</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z50f7292dbd4e4778b78fd83e8b029fd4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">5.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;"><u>Contributions</u></font>.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z7f4c004d5cec40058503adfc96a88b5d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">5.1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Responsibilities of Hemispherian</u>. In connection with the Collaboration and the Asset Transfer Agreement, in consideration to its Share Capital holdings, Hemispherian will transfer and assign to the Company all worldwide rights in
              and to the Transferred Assets, all as set forth, defined, and subject to the terms and conditions of the Asset Transfer Agreement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z97d3913e812741d6a92892db0500f0ae" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">5.2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Responsibilities of BioLine.</u> Subject to Section 4, BioLine shall provide ongoing funding for all activities conducted under the Collaboration, in accordance with the Budget, and such funds shall be used as working capital for the
              development and commercialization of the Products. BioLine shall be responsible for managing and implementing the Company&#8217;s development activities in accordance with the Development Plan, as well as for the ongoing operations, management,
              budget, and expenses of the Company.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z3d4fa45ed2574cc2a99e25e7540ceb1e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">5.3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Advisory Fee</u>. In addition to any direct charges for specific personnel engaged in the performance of the Development Plan as may be required pursuant to Section 5.4 below, the Company shall pay Hemispherian a monthly advisory fee of
              US$80,000 (inclusive of any and all taxes), commencing following thirty (30) days from the Asset Transfer Closing Date (as defined in the Asset Transfer Agreement), and continuing for the earlier of (a) twenty-four (24) months, or (b) the
              termination of the Collaboration and/or this Agreement under any of the events described in Section&#160;17 below.&#160;For the avoidance of doubt, the advisory fee payable under this Section 5.3 shall be in addition to, and not deducted from, the
              funding requirements set forth in Section 4.1 and shall not be considered part of the Threshold Amount to be invested by BioLine<font style="font-weight: bold;">.</font></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z4cdd23c1b3924ecfb803ceccbb01a3f3" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">5.4.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Contracting Services</u>. If the Company requires the involvement of any personnel from either BioLine or Hemispherian to support its development activities, regardless of any other agreement that may be in place, BioLine or
              Hemispherian shall provide contracting services pursuant to customary engagement agreements with the Company, and all related costs shall be charged to the Company at cost plus a defined markup, which markup shall be uniform for transactions
              between the Company and either BioLine or Hemispherian, as relevant, and as determined by a transfer-pricing study. The Parties agree that any transfer-pricing study required to determine the defined markup for contracting services under this
              Section 5.4 shall be coordinated in good faith between BioLine and Hemispherian. The costs and expenses of such transfer-pricing study shall be borne by the Company.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zb51af246d470481f8462b9c869115c8b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">5.5.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Steering Committee</u>. The Parties will establish a steering committee (the &#8220;<font style="font-weight: bold;">SC</font>&#8221;) that will oversee the high-level development, clinical and regulatory decisions with respect to the Products. The
              SC will meet once monthly, or at other intervals as may be agreed by the Parties. Each of the Shareholders will have equal representation on the SC, and they will act reasonably to achieve consensus. In the event that the Parties are unable
              to resolve disagreements that may arise within the SC, the matter will be referred to the Board for resolution.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zd6dbd3e7e2054a4da8c3e8ab1bbc8b91" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">5.6.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Notwithstanding anything to the contrary herein, Section 7.1 of the Asset Transfer Agreement is hereby incorporated by reference into this Agreement and shall be deemed to form an integral part hereof. BioLine shall have the right to
              enforce the obligations and actions set forth in Sections 7.1 of the Asset Transfer Agreement as if it were a direct beneficiary under the Asset Transfer Agreement, and may require performance of such obligations to the same extent as the
              Company.</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="zb84271d6206e4a52a8e27ee48ed8970c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">6.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;"><u>Board of Directors</u></font>.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="za1fa0b7d582a430082d22a412b415f7b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">6.1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Election of Directors</u>. The Board of Directors of the Company (the &#8220;<font style="font-weight: bold;">Board</font>&#8221;) shall consist of up to four (4) directors, to be designated as follows:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="ze97d81f9eee741e582f45a18001da147" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 127.55pt;"><br>
          </td>
          <td style="width: 70.9pt; vertical-align: top;">6.1.1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>BioLine shall be entitled to appoint, dismiss and replace two (2) directors to the Board (each, a &#8220;<font style="font-weight: bold;">BioLine Director</font>&#8221;), who shall initially be Dr. Ella Sorani, and Mr. Philip A. Serlin, as well as the
              sole right to nominate the Chairman of the Board, who will be one of the BioLine Directors (initially, Mr. Philip A. Serlin);</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zeb0318756c3b4edf9c0e4cb4c0fb0757" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 127.55pt;"><br>
          </td>
          <td style="width: 70.9pt; vertical-align: top;">6.1.2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Hemispherian shall be entitled to appoint, dismiss and replace two (2) directors to the Board (each, a &#8220;<font style="font-weight: bold;">Hemispherian Director</font>&#8221;), who shall initially be Mr. Zeno Albisser, and Dr. Adam Robertson.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zc5824e8cfda541faa236ebb970a1016d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">6.2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Removal/Replacement</u>. No director of the Company designated pursuant to Section 6.2 of this Agreement may be removed and/or replaced, unless (i) those Shareholders who designated such director pursuant to Section 6.2 so request such
              removal by written notice to the Company, or (ii) the Person(s) originally entitled to designate such director pursuant to Section 6.2 is no longer entitled to designate such director.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z07370f881db04256b2208461df97ae65" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">6.3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Vacancies</u>. In the event that a vacancy is created on the Board by the death, disability, retirement, resignation or removal of a director, or otherwise there shall exist or occur any vacancy on the Board, each Shareholder hereby
              agrees to vote or take action by written consent, in each case, to the extent such Shareholder shall be entitled to do so, to cause the vacancy to be filled by a designee of the group of Shareholders which had designated or was entitled to
              designate the director whose position has become vacant pursuant to Section 6.1, or by a designee of the Board by unanimous consent, as applicable.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z4b6dba6ce4144a0fba6b45eee5207983" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">7.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;"><u>Management</u></font>.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z13f27283d7bb4049b089a7cd02361ddc" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">7.1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The powers, responsibilities, and procedures with respect to the Company&#8217;s shareholders, the Board and officers of the Company shall be as specified in this Agreement, and the Articles of Association of the Company.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z8a99c0ec876949d4b0732eaf027ba4b1" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">7.2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The Board will meet on a quarterly basis (or at other intervals as may be agreed by the Parties) and may convene by teleconference.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z565e32069f4243daa7d6a8f281856784" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">7.3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Unless otherwise provided by this Agreement, matters presented at meetings of the Board shall be decided upon by all of the votes of directors, whether present (or participating, in the case of a vote through a permitted means of
              communications) and lawfully entitled to vote thereon. Each director shall have a single vote subject to Section 7.4 below. Resolutions of the Board shall be adopted by majority vote unless otherwise provided by this Agreement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z94ec7b5dd6e245ef9c06c02c2be7ae6e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">7.4.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>One of the BioLine Directors shall serve as Chairman of the Board and shall have a casting vote in the event of a deadlock.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z1c79e8ada6f4482db73c4b8aae5baf97" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">8.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;"><u>Restrictions on Transfer </u></font>&#160; Except in the case of an M&amp;A Event, and for so long as this Agreement remains in effect, no Shareholder shall transfer, assign, convey, pledge, grant any
              security interest or gift, or otherwise dispose any of its securities in the Company (each a &#8220;<font style="font-weight: bold;">Transfer</font>&#8221;), without the prior written consent of the other Shareholder. Notwithstanding the foregoing, this
              restriction shall not apply to any transfer or pledge made pursuant to that certain loan facility entered into between BioLine and Kreos Capital VII Aggregator SCSP dated September 14, 2022, as amended from time to time (or any replacement
              facility thereof to the extent that BioLine enters into a refinancing arrangement with another financial institution) (the &#8220;<font style="font-weight: bold;">Kreos Agreement</font>&#8221;). To the extent a Transfer was approved pursuant to this
              Section 8, as a condition precedent to any such approved Transfer, the transferee thereof shall become a Party to this Agreement by executing a countersignature page of this Agreement or other instrument approved by the Board, pursuant to
              which, among other things, such transferee shall agree to be bound by and subject to the terms of this Agreement as a Shareholder, and thereafter such Person shall be deemed a Shareholder for all purposes under this Agreement. Notwithstanding
              the foregoing or anything to the contrary herein, the provisions of this Section 8 shall not apply (a) in the case of a Shareholder, upon a Transfer by the Shareholder to its shareholders, members, partners or other equity holders or any
              other Affiliate; <u>provided</u> that in the case of <u>clause(s)</u>&#160;<u>(a)</u> or <u>(b)</u>, the Shareholder shall deliver prior written notice to the Company and the other Shareholders of such Transfer and such securities of the
              Company shall at all times remain subject to the terms and restrictions set forth in this Agreement and such transferee shall, as a condition to such Transfer, deliver a counterpart signature page to this Agreement as confirmation that such
              transferee shall be bound by all the terms and conditions of this Agreement as a Shareholder (but only with respect to the securities so Transferred to the transferee); and <u>provided</u>&#160;<u>further</u> in the case of any transfer pursuant
              to <u>clause (a)</u> or <u>(c)</u> above, that such Transfer is made pursuant to a transaction in which there is no consideration actually paid for such Transfer.</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z05fa38aff35042ba9ae0708370bd1b52" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">9.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;"><u>Bring Along</u></font>.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zd14570ed878a4d12a257ad3d48ec6981" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">9.1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Subject to Section 12&#160;<font style="font-style: italic;">(Major Decisions</font>), if the Shareholders of the Company holding a simple majority of the voting power of the Company (i.e., over 50%) (the &#8220;<font style="font-weight: bold;">Selling



                Shareholders</font>&#8221;), together with the Board, approved and accepted a transaction or series of related transactions with any person or persons regarding a sale, whether through a purchase, merger or otherwise, of all, or substantially all
              of the Company securities or a sale of all or substantially all of the Company&#8217;s assets (the &#8220;<font style="font-weight: bold;">Transaction</font>&#8221;), then such decision shall be binding upon all Shareholders, and all of the Shareholders will
              not object to, shall vote their shares in favor of, shall execute the relevant documents in connection with, waive any dissenters&#8217; rights, appraisal rights or similar rights in connection with such Transaction and otherwise take all necessary
              and reasonable actions relating to the consummation of such Transaction.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z82016db16aa046a18ebadf7a91fd8019" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">9.2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>If such Transaction is conditioned upon the sale of all remaining shares of the Company to such third party (a &#8220;<font style="font-weight: bold;">Sale of Shares Transaction</font>&#8221;), then all Shareholders of the Company shall be required to
              sell their shares in such Sale of Shares Transaction, on the same terms as to price per share, payment terms, escrow provisions, indemnification obligations, representations and warranties of shareholders, confidentiality provisions and any
              other terms relating to their shares or their rights and privileges as shareholders of the Company; provided, however, that (i) no Shareholder shall be liable for the breach of any representation, warranty or covenant made by any other Person
              in connection with the Sale of Shares Transaction, other than the Company (except to the extent that funds may be paid out of an escrow, holdback or earn-out established to cover breaches of representations, warranties and covenants of the
              Company as well as breach by any Shareholder of any of identical representations, warranties and covenants provided by all Shareholders); (ii) liability of any Shareholder for indemnification in the Sale of Shares Transaction shall be limited
              to such Shareholder&#8217;s applicable share (determined based on the respective proceeds payable to each Shareholder in connection with such Sale of Shares Transaction in accordance with the provisions of the Company&#8217;s Articles of Association, as
              may be amended from time to time) of a negotiated aggregate indemnification amount that applies equally to all indemnifying Shareholders but that in no event exceeds the amount of consideration payable to such Shareholder&#160; in connection with
              such Sale of Shares Transaction (including amounts placed in escrow or otherwise held for such Shareholder for indemnification purposes), except with respect to claims related to fraud by such Shareholder, the liability for which need not be
              limited as to such Shareholder; and (iii) no Shareholder shall be required to agree (unless such Shareholder is a Company officer, director, or employee) to any restrictive covenant in connection with the Transaction (including, without
              limitation, any covenant not to compete or covenant not to solicit customers, employees or suppliers of any party to the Transaction) or any release of claims other than a release in customary form of claims arising solely in such
              Shareholder&#8217;s capacity as a shareholder of the Company.</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zbe9d5e5805d8401e9a04272ab20a3336" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">9.3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>All holders of record of Share Capital shall be given written notice of the Sale of Shares Transaction and the date designated for the closing thereof (the &#8220;<font style="font-weight: bold;">Sale Closing</font>&#8221;). Notice of the occurrence
              of the Sale of Shares Transaction and the date designed for the Sale Closing will be given at least [***] days in advance. Upon receipt of such notice, each holder of shares of Share Capital shall surrender his, her or its certificate or
              certificates for all such shares to the Company at the place designated in such notice and shall thereafter receive the consideration payable in such Sale of Shares Transaction for such holder&#8217;s shares of Share Capital, if applicable. On the
              Sale Closing, all shares of Share Capital shall be deemed to have been sold, transferred or exchanged in connection with the Sale of Shares Transaction, and all rights of the holders of Share Capital with respect to the capital shares so
              sold, transferred or exchanged, will terminate, except only the rights of the holders thereof, upon surrender of their certificate or certificates therefor, to receive the consideration payable to such holders for their shares in the Company
              which have been sold, transferred or exchanged, if any. If so required by the Company, certificates surrendered for conversion shall be endorsed or accompanied by a written instrument or instruments of transfer, in form satisfactory to the
              Company, duly executed by the registered holder or by his, her, or its attorney duly authorized in writing.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z5f6cbe371f2a407a9348425b7ee2484b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">9.4.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>All certificates evidencing shares of Share Capital which are required to be surrendered for sale, transfer or exchange in accordance with the provisions hereof shall, from and after the Sale Closing, be deemed to have been retired and
              cancelled and the shares of Share Capital represented thereby sold, transferred or exchange for the consideration payable thereupon, for all purposes, notwithstanding the failure of the holder or holders thereof to surrender such certificates
              on or prior to such Sale Closing.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z3ae2d750e1a64e5daa9cc32047592bca" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">9.5.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Each of the Shareholders hereby agrees (a) to execute and deliver all related documentation and take such other action in support of the Transaction as shall reasonably be requested by the Company or the Selling Shareholders in order to
              carry out the terms and provision of this Section 9, including without limitation executing and delivering instruments of conveyance and transfer, and any purchase agreement, merger agreement, indemnity agreement, escrow agreement, consent,
              waiver, governmental filing, share certificates duly endorsed for transfer (free and clear of impermissible liens, claims and encumbrances) and any similar or related documents; and (b) to refrain from exercising any dissenters&#8217; rights or
              rights of appraisal or similar rights under Applicable Law at any time with respect to such Transaction.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z016a0e7ae29c48b48f030bba2570a23a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">10.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;"><u>No Rights to Participate in Future Share Issuances. </u></font>Notwithstanding anything to the contrary under any Applicable Law or arrangement, and except for the rights expressly set forth in Section
              4.3 above, no Shareholder shall have any right to participate in any future issuances of shares or other securities by the Company, whether by way of pre-emptive rights, rights of first offer, rights of first refusal, or otherwise, unless
              otherwise expressly provided in this Agreement. For the avoidance of doubt, this provision shall be incorporated into the Company&#8217;s Articles of Association.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zeaece6ed0540457d979ae0b6191249ef" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">11.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#160;<font style="font-weight: bold;"><u>No Other Shareholder Agreement</u></font>. None of the Shareholders shall enter into any agreements amongst themselves or with any other shareholder or other holder of equity of the Company, whether
              oral or written, with respect to the Company, which agreement is intended to circumvent such Shareholders&#8217; obligations under this Agreement.</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z614e495c45e94d998831a7c3ab4b4046" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">12.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;"><u>Major Decisions Requiring the Approval of a BioLine Director and a Hemispherian Director</u></font>. For as long as this Agreement is in effect and has not been terminated pursuant to its terms, the
              Company shall not, either directly or indirectly by, amendment, merger, consolidation, reorganization or otherwise, do any of the following without (in addition to any other vote required by law or the Company&#8217;s Articles of Association
              Articles of Association) first obtaining the approval (by vote or written consent, as provided by law) of at least one BioLine Director and at least one Hemispherian Director:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zb6eb2939ca314979a15b5318fbef55af" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">12.1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Enter or consent to a Liquidation;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="za6c3ffd95f4a4bf0b6dbb280b34ddc4b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">12.2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Except with respect to a Qualified Financing, amend, replace or modify to any provision of the Company&#8217;s Articles of Association or any other Company&#8217;s corporate documents, in a manner that adversely effects the rights of the Shareholders,
              <font style="font-style: italic;">provided, however</font>, that the authorization or issuance of a more senior class or series of shares, or authorization or issuance of shares of a class ranking <font style="font-style: italic;">pari passu</font>
              shall not be considered as an action adversely affecting the rights of the Shareholders, provided such acts occur in connection with a Qualified Financing;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z59189bd0a1bb473ab6c3d09e3397a3a3" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">12.3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Except with respect to a Qualified Financing, (i) increase or decrease the authorized number of shares of any class or series of shares, (ii) alter or change any of the powers, preferences, privileges or rights of the Shareholders; or
              (iii) increase or decrease the size of the Board;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z92e74e963da54f78802f5b250a84f172" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">12.4.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Effect or undertake to effect any IPO other than a QIPO;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z882f62114d6b4e8ebce7871b044e4709" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">12.5.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Except with respect to a Qualified M&amp;A, effect any M&amp;A Event;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z4cc781b522714fb886d76c7f9a2b19a5" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">12.6.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Except with respect to a Qualified Financing and excluding any funding provided by BioLine to the Company pursuant to the terms of this Agreement, authorize any financing or private placement in the Company, or create or authorize the
              creation of any debt security;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z495bc9f32adf4ec8ae9449c1cc26db99" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">12.7.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Make any investments into or acquisitions of any businesses or assets in an aggregate excess of US$[***] in the aggregate, or US$[***] in a single transaction; provided, however, that this restriction shall not apply to purchases of drug
              related products and/or other inventory-related items required by the Company in its ordinary course of business;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z5437f15a2e4a499c9d700b3f1f1e664d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">12.8.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Entering into any interested party transaction, except for (i) transactions entered into in the ordinary course of business and at arm&#8217;s length terms that do not exceed US$[***] (other than services provided by BioLine pursuant to a
              services agreement executed with the Company); (ii) transactions between the Company and its wholly-owned subsidiaries, (iii) any funding provided by BioLine to the Company pursuant to the terms of this Agreement or by Hemispherian pursuant
              to Section 4.3 of this Agreement;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z3223078630734174bf51d0f6d1fcb5bc" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">12.9.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Sell, transfer, assign or license all or substantially all of the Company&#8217;s intellectual property.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; margin-left: 40.5pt; line-height: 1.25;">The aforesaid shall apply, <font style="font-style: italic;">mutatis mutandis</font>, with respect to any Affiliate of the Company.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z750c2879584c43b59a9d1ab6bbefbceb" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">13.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;"><u>Confidentiality</u></font>.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zd604c3ae7e534b8fb6baf5f34461cb41" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">13.1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Each Party acknowledges that in connection with this Agreement it may gain access to Confidential Information of the other Parties. Each Party agrees: (a) to keep confidential the Confidential Information of the other Parties; (b) not to
              disclose such Confidential Information to any third party without the prior written consent of the disclosing Party; (c) to use such Confidential Information only for the purposes of performing its obligations or exercising its rights under
              this Agreement; and (d) to take all reasonable precautions to prevent unauthorized disclosure or use of such Confidential Information, including, without limitation, ensuring that each of its employees, officers, directors, and agents who has
              access to such Confidential Information is aware of and complies with the confidentiality obligations under this Agreement.</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zedd138de85294079bfaf586c05390242" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">13.2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The obligations set forth in Section 13.1 shall not apply to Confidential Information that: (a) is or becomes publicly known through no fault of the receiving Party; (b) was known to the receiving Party prior to disclosure by the
              disclosing Party, as evidenced by the receiving Party&#8217;s written records; (c) is rightfully received from a third party without a duty of confidentiality; (d) is independently developed by the receiving Party without use or reference to the
              disclosing Party&#8217;s Confidential Information, as evidenced by the receiving Party&#8217;s written records; or (e) is required to be disclosed by law or court order, provided that the receiving Party gives the disclosing Party prompt notice of such
              requirement and cooperates with the disclosing Party in seeking a protective order or other appropriate remedy.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zff8465c04b764d98b3ee65b49b841882" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">13.3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The obligations set forth in this Section 13 shall survive for five (5) years following termination of this Agreement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zac3aa096540f4ef1bd316a046e442f30" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">13.4.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Upon termination of this Agreement or upon the disclosing Party&#8217;s request, the receiving Party shall promptly either (i) return to the disclosing Party, or (ii) destroy, all Confidential Information of the disclosing Party in its
              possession, including all copies and extracts thereof.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z42dc36712c0948f3bacf15ef8c19caed" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">14.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;"><u>Information Rights</u></font>. The Company shall deliver to each Shareholder any information required to be provided under Applicable Law.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z8974524b5e474e5fb067f59c1e2c92f4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">15.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;"><u>Public Announcements; Disclosure Requirements</u></font>. No Party shall make, or cause to be made, any press release, public announcement, or other public disclosure concerning the existence or terms of
              this Agreement or the transactions contemplated hereby without the prior written consent of the other Parties, except as may be required by Applicable Law, regulation, or the rules of any stock exchange or securities market on which such
              Party or its affiliates&#8217; securities are listed or traded. Notwithstanding the foregoing, the Parties acknowledge that BioLine is a publicly traded company listed on the Nasdaq Stock Market and may be required to make public disclosures or
              filings regarding this Agreement or related transactions in accordance with applicable securities laws and Nasdaq rules. In such event, BioLine shall, to the extent practicable and permitted by law, provide the other Parties with a reasonable
              opportunity to review any such proposed disclosure prior to its release.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zd3408efa49b7472ead111cd3b591a77d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">16.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;"><u>Non-Compete</u></font>.&#160;The Parties acknowledge the special terms set out in Section 10.3 of the Asset Transfer Agreement regarding Hemispherian&#8217;s right to continue to research, develop and commercialize
              Non-Selected Compounds for any indications <font style="font-style: italic;">other than</font> the Specified Indications (as such terms are defined in the Asset Transfer Agreement). Such terms are hereby incorporated by reference into this
              Agreement and the restriction on Hemispherian from engaging in any activity in the Specified Indications shall be deemed to have been made by Hemispherian towards both BioLine and the Company as if fully set forth herein.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z84a576842972491c8da0397ee24dc3c6" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">17.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;"><u>Term and Termination</u></font>.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z5f07e1728cf6439088b213147bfb468a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">17.1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>This Agreement shall be effective as of the Effective Date and shall continue in effect until, and shall terminate upon, the earliest to occur of (a) the termination of the Agreement by the Parties in accordance with Section 17.3 hereof,
              (b) the date on which BioLine has notified Hemispherian that it is no longer funding the Company (by way of a formal notice that BioLine will not make new contributions to the Company, either through equity or otherwise), (c) the Shareholders
              consenting to a Liquidation of the Company or the Company entering into a Liquidation, and (d) upon the consummation of an M&amp;A Event or IPO by the Company (as applicable, the &#8220;<font style="font-weight: bold;">Term</font>&#8221;). In each such
              case, the Agreement shall not terminate automatically but rather each Shareholder shall have the right to provide notice to the other Shareholder that the Agreement is hereby terminated and deemed null and void.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zcc5f7c7c87d94360a22a3b8561bda794" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">17.2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The provisions of Sections 12.9, 13, 15, 16, and 20 shall survive termination.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z6363621594e943868c8f5564c5508582" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">17.3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>If the Company (i) ceases or suspends operations for a period of three (3) consecutive months during the first year of the Company&#8217;s operations due to insufficient financial resources, (ii) ceases or suspends operations for a period of six
              (6) consecutive months during the second year of the Company&#8217;s operations due to insufficient financial resources, or (iii)&#160;ceases or suspends operations for a period of twelve (12) consecutive months of the Company&#8217;s operations due to
              insufficient financial resources any time after that, either Hemispherian or BioLine may terminate this Agreement and/or initiate a process of Liquidation of the Company by providing written notice to the other party at which point in time
              this Agreement shall be deemed null and void.</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <br>
    <table cellspacing="0" cellpadding="0" id="z76a245fb47014dc5bade3dcfc5177858" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">18.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;"><u>Representations and Warranties of the Shareholders</u></font>. Each of the Shareholders represents and warrants to the other Shareholder and the Company, severally and not jointly, as of the date hereof
              that:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z27c83dc661c84af0afedd34a6f355e64" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">18.1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Authority and Validity</u>. Such Shareholder has the full right, power, and authority to enter into this Agreement and the Related Agreements, and to perform its obligations hereunder, and this Agreement and the Related Agreements,
              constitutes its legal, valid, and binding obligation, enforceable against it in accordance with its terms.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z8c034a3355a44b1db10f5c7ac1786248" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">18.2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Absence of Conflicts</u>.<font style="font-weight: bold; font-variant: small-caps;">&#160;</font>The execution and delivery of this Agreement and the Related Agreements by such Shareholder and the consummation of the transactions as
              contemplated hereunder (i) do not and will not violate or conflict with any statute, regulation, judgment, order, writ, decree, or injunction currently applicable to such Shareholder , or any of such Shareholder&#8217;s property or assets; (ii) do
              not and will not violate or conflict with any patent, patent application or any existing mortgage, indenture, contract, licensing agreement, financing statement, or other agreement binding on such Shareholder; and, in the case of BioLine
              (iii)&#160;has the financial ability to execute and perform its financial obligations under this Agreement solely with respect to the provision of the Threshold Amount and any coverage of the Advisory Fee pursuant to Section 5.3. The execution and
              performance of this Agreement and the Related Agreements will not violate any agreement, policies or procedures of any other person or entity, by whom such Shareholder is currently or in the future employed or engaged or has been employed or
              engaged in the past, or for which such Shareholder is currently or in the future perform services or has performed services in the past.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z72a5d26e9db74bde94532735dc0c60e2" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">18.3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Consents and Contractual Restrictions</u>. No consents or approvals of any third party are required in connection with the execution and delivery of this Agreement and the Related Agreements or the performance of the transactions
              contemplated hereunder by such Shareholder. No contract, agreement or arrangement binding upon such Shareholder, including any agreement or arrangement with a previous or current employer of such Shareholder, restricts his ability to fulfill
              his obligations and responsibilities under this Agreement and the Related Agreements or any related agreement or to carry out the activities contemplated herein.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z6342b108e2bb483ca1774056bae3527f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">18.4.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Litigation and Governmental Orders</u>.&#160; (i)&#160;There are no legal actions pending or, to the knowledge of such Shareholder, threatened against such Shareholder or any of the assets or properties of such Shareholder, that would impair the
              ability of such Shareholder to perform its obligations under this Agreement and/or to consummate the transactions contemplated thereby; and (ii) the Shareholders and their respective assets and properties are not subject to any governmental
              order that would materially impair either Shareholder from performing its obligations under this Agreement or consummating the transactions contemplated hereby.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 0.55pt; margin-left: 35.45pt; line-height: 1.25;">The representations and warranties provided by Hemispherian to the Company under Sections 4 and 5 of the Asset Transfer Agreement are hereby incorporated by
      reference into this Agreement and shall be deemed to have been made by Hemispherian to both BioLine and the Company as if fully set forth herein.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">Notwithstanding anything to the contrary herein, Sections 6.1 and 6.2 of the Asset Transfer Agreement are hereby incorporated by reference into this Agreement and shall be
      deemed to form an integral part hereof. BioLine shall have the right to enforce the obligations and actions set forth in Sections 6.1 and 6.2 of the Asset Transfer Agreement as if it were a direct beneficiary under the Asset Transfer Agreement, and
      may require performance of such obligations to the same extent as the Company.</div>
    <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="zf1590b205f4a4c9dab76f857c411fa80" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">19.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;"><u>Indemnification for certain Israeli Tax Liability</u></font>. Notwithstanding anything to the contrary herein, BioLine hereby agrees to indemnify Hemispherian from and against fifty percent (50%) of
              Hemispherian&#8217;s final tax liability in Israel arising directly from any dividend distributions by the Company, after taking into account and applying any available offsets, including foreign tax credits and other deductions to which
              Hemispherian is entitled. The Parties agree that such indemnification shall be limited to the portion of the Israeli tax liability that remains after all applicable credits and deductions have been utilized by Hemispherian, and shall not
              exceed fifty percent (50%) of such net liability. Hemispherian shall use commercially reasonable efforts to obtain and apply all available foreign tax credits, offsets, and deductions with respect to any Israeli tax liability arising from
              dividend distributions by the Company. Hemispherian shall promptly provide BioLine with all documentation and information reasonably requested by BioLine evidencing such efforts and the calculation of any applicable credits, offsets,
              deductions, and resulting net Israeli tax liability. If the Parties disagree as to whether all reasonable efforts have been made or as to the calculation of the net Israeli tax liability, such dispute shall be resolved in accordance with the
              dispute resolution provisions of this Agreement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">Notwithstanding the foregoing, if, after BioLine has made any indemnification payment to Hemispherian under this Section, Hemispherian subsequently receives a refund, rebate or
      tax credit covering&#160; any portion of the Israeli tax liability for which indemnification was paid, or if for any reason the final Israeli tax liability is reduced (including as a result of a tax audit, amended return, or other adjustment),
      Hemispherian shall promptly repay BioLine an amount equal to the indemnification payment previously received from BioLine with respect to such refunded or reduced liability. Any repayment by Hemispherian to BioLine under this Section shall not be
      subject to any set-off or tax withholding.</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zf29627560ee34b4b8d9eb1574bad27fe" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 14.2pt;"><br>
          </td>
          <td style="width: 21.25pt; vertical-align: top;">20.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#160;<font style="font-weight: bold;"><u>Governing Law and Dispute Resolution.</u></font></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z8904b546cd134453898a2cdd1f0406ab" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">20.1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Governing Law</u>. This Agreement is governed by and shall be construed in accordance with the laws of England and Wales, subject to the application of mandatory laws in the Company&#8217;s jurisdiction of incorporation.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zb8a8803dca074dfe92d99d714061efda" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">20.2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Disputes</u>. All disputes arising out of or in connection with this Agreement, including any question regarding its existence, validity, or termination (&#8220;<font style="font-weight: bold;">Dispute</font>&#8221;), shall be submitted to the
              decision of the chief executive officers of the Parties, who shall make their best efforts to settle such matters amicably through good faith discussions In the event that the chief executive officers are unable to reach an agreement with
              respect to the Dispute within 15 days after the Dispute was submitted to them, the Dispute shall be submitted to the decision of the chairpersons of the Parties, who shall make their best efforts to settle such matters amicably through good
              faith discussions.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z77bc355921154f2992ea685132c09ecf" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">20.3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Arbitration</u>. In the event that the chairpersons fail to reach an agreement with respect to the Dispute within 15 days after the Dispute was submitted to them, the Dispute may be referred by either Party to and finally resolved by
              arbitration administered by the International Chamber of Commerce (&#8220;<font style="font-weight: bold;">ICC</font>&#8221;) in accordance with the International Arbitration Rules for expedited arbitration then in force (the &#8220;<font style="font-weight: bold;">Rules</font>&#8221;), which rules are deemed to be incorporated by reference into this section, and as modified by the following provisions: (i) the governing law provision set out in Section 19.1 above shall apply to the substantive (but
              not procedural) aspects of the arbitration; (ii) the seat of arbitration shall be Geneva, Switzerland; (iii) the arbitral tribunal shall consist of one arbitrator, unless the Parties cannot reach agreement on the identity of such arbitrator
              within 30 days of the matter being referred to arbitration, in which case the tribunal shall consist of three arbitrators who will be selected in accordance with the Rules; (iv) the language of the arbitration shall be English; (v) judgment
              upon any award and/or order may be entered in any court having jurisdiction thereof; and (vi) when a Dispute occurs and is subject to arbitration under this section, except for the matters subject to such Dispute, the Parties shall continue
              to exercise, perform, and fulfill their respective rights, duties, and obligations, as the case may be, under and in accordance with the provisions of this Agreement. The foregoing arrangements shall not derogate from a Party&#8217;s right to seek
              injunctive relief from a court of competent jurisdiction.</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="zb4067fa60a7c4d78a7a27a35e027363b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">21.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-weight: bold;"><u>Miscellaneous</u></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z92d58b64b4fa42bda9d24d78aba79c4f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">21.1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>At any time or from time to time after the date hereof, the Parties agree to cooperate with each other, and at the request of any other Party, to execute and deliver any further instruments or documents and to take all such further action
              as the other party may reasonably request in order to carry out the intent of the Parties hereunder.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z445630f9496c47d086334b948ab216e2" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">21.2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Any term of this Agreement may be amended and the severance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively) and this Agreement may be terminated only with
              the written consent of all Parties or pursuant to the terms of Section 17 above.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z975e4d1483e3403a91fb5b0c8816a6f0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">21.3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each Party and delivered to the
              other Party, it being understood that two Parties need not sign the same counterpart. In the event that any signature is delivered by email, such signature shall create a valid and binding obligation of the Party executing (or on whose behalf
              such signature is executed) the same with the same force and effect as if such email signature page were an original thereof.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z7abe66c9b8774edb8bd6580ff74a0526" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">21.4.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>This Agreement, together with the Related Agreements, constitute the full and entire agreement, covenants, promises and understandings between the Parties hereto with respect to the subject matter hereof, and supersede any and all prior
              agreements, understandings, promises and representations made by all or some of the Parties (or by any Party to another), written or oral, concerning the subject matter hereof and the terms applicable hereto, including without limitation, the
              LOI and the document titled &#8220;Proposed structure of definitive JV transaction documents (Arnon-June 18, 2025)&#8221; (the &#8220;<font style="font-weight: bold;">Proposal</font>&#8221;), which LOI and Proposal shall be deemed null and void effective as of the
              Effective Date.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <table cellspacing="0" cellpadding="0" id="za478f8a6173f49a5a82d02dcef82f4f8" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">21.5.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>All notices or other communications provided for in this Agreement shall be in writing and shall be given in person, by registered mail (registered air mail if mailed internationally), by an overnight courier service which obtains a
              receipt to evidence delivery, by electronic mail, addressed as set forth below:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="031e78da066d4cf79aa0fe9d28a32884" class="DSPFListTable">

        <tr>
          <td style="width: 111.135pt;"></td>
          <td style="width: 72pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">Company</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="line-height: 1.25;">Tetragon Biosciences Ltd.</div>
            <div style="line-height: 1.25;">Address: 2 HaMa&#8217;ayan Street, Modi&#8217;in 7177871, Israel&#160;</div>
            <div style="line-height: 1.25;">Phone: [***]</div>
            <div style="line-height: 1.25;">Attn:</div>
            <div style="line-height: 1.25;">E-mail: [***]</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="0b75ac5b5a5247008491ee657d7110df" class="DSPFListTable">

        <tr>
          <td style="width: 111.135pt;"></td>
          <td style="width: 72pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">BioLine</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="line-height: 1.25;">BioLineRx Ltd.</div>
            <div style="line-height: 1.25;">Address:&#160;2 HaMa&#8217;ayan Street, Modi&#8217;in 7177871, Israel&#160;</div>
            <div style="line-height: 1.25;">Phone: [***]</div>
            <div style="line-height: 1.25;">Attn: Mali Zeevi</div>
            <div style="line-height: 1.25;">E-mail: [***]</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="9cd943e98619498796ebff1e241ca47e" class="DSPFListTable">

          <tr>
            <td style="width: 111.135pt;"></td>
            <td style="width: 72pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Hemispherian</div>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="line-height: 1.25;">Hemispherian AS</div>
              <div style="line-height: 1.25;">Address: L&#248;renveien 73A, 0585 Oslo, Norway</div>
              <div style="line-height: 1.25;">Phone: [***]</div>
              <div style="line-height: 1.25;">Attn: Zeno Albisser</div>
              <div style="line-height: 1.25;">E-mail: [***]</div>
            </td>
          </tr>

      </table>
      <br>
    </div>
    <div style="text-align: justify; margin-left: 111.35pt; line-height: 1.25;">or such other address as any Party may designate to the other in accordance with the aforesaid procedure. All notices and other communications delivered in person, or by
      electronic mail, shall be deemed to have been given as of one Business Day after sending thereof, all notices and other communications delivered by overnight air courier shall be deemed to have been given as of the third Business Day after posting;
      and all notices and other communications sent by registered mail shall be deemed given ten (10) days after posting.</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z3e4b43b092794cb5b356e4f5b0422d6b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.5pt;"><br>
          </td>
          <td style="width: 70.85pt; vertical-align: top;">21.6.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>If any provision of this Agreement is held to be unenforceable under Applicable Law, then such provision shall be excluded from this Agreement and the remainder of this Agreement shall be interpreted as if such provision were so excluded
              and shall be enforceable in accordance with its terms; provided, however, that in such event this Agreement shall be interpreted so as to give effect, to the greatest extent consistent with and permitted by Applicable Law, to the meaning and
              intention of the excluded provision.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">[Signature Page to Follow]</div>
    <div style="text-align: center; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">IN WITNESS WHEREOF </font>the Parties have signed this Collaboration and Shareholders Agreement as of the date first hereinabove set forth.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: Arial; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zaabf7925c59642cf9247d2f46c9d4c53">

          <tr>
            <td style="width: 50%; vertical-align: middle;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman';">COMPANY:</div>
            </td>
            <td style="width: 50%; vertical-align: middle;">
              <div style="line-height: 1.25; font-family: 'Times New Roman';">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: middle;">
              <div style="line-height: 1.25; font-family: 'Times New Roman';">&#160;</div>
            </td>
            <td style="width: 50%; vertical-align: middle;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman';"><u>/s<font style="font-style: italic;">/ </font>Philip Serlin</u></div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman';">Tetragon Biosciences Ltd.</div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman';">By: Philip Serlin</div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman';">Title: Chairman of the Board</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25"> </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <br>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">IN WITNESS WHEREOF </font>the Parties have signed this Collaboration and Shareholders Agreement as of the date first hereinabove set forth.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="495b45232411427b8d23a5fd185cd130">

        <tr>
          <td style="width: 50.00%;" rowspan="1">SHAREHOLDERS:</td>
          <td style="width: 50.00%;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50.00%;">&#160;</td>
          <td style="width: 50%;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman';"><u>/s</u><font style="font-style: italic;"><u>/ </u></font><u>Philip Serlin</u></div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman';">BioLineRx Ltd.</div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman';">By: Philip Serlin</div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman';">Title: Chief Executive Officer</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman';"><u>/s</u><font style="font-style: italic;"><u>/ </u></font><u>Paul Lelieveld</u></div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman';">Hemispherian AS</div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman';">By: Paul Lelieveld</div>
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman';">Title: Chairman of the Board</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <br>
    <div style="text-align: center; line-height: 1.25;"><u>Schedule </u><u>1.3.4</u></div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><u>Budget</u></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">[***]</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <br>
    <div style="text-align: center; line-height: 1.25;"><u>Schedule </u><u>1.3.9</u></div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><u>Development Plan</u></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">[***]</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <br>
    <div style="text-align: center; line-height: 1.25;"><u>Schedule&#160;1.3.92.2</u></div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><u>Articles of Association</u></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">[***]</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="line-height: 1.25;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 25.8.1.5328
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
  <div style="text-align: right;"> <u><font style="font-weight: bold;">Exhibit 99.1</font></u> </div>
  <div> <br>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="z6b15a1c07b02410c96bb21d7838117e9">

        <tr>
          <td style="width: 50%;">
            <div class="BRPFPageHeader">
              <div style="text-align: left; line-height: 1.25;"><img width="163" height="38" src="image00003.jpg"></div>
            </div>
          </td>
          <td style="width: 50%; text-align: right; vertical-align: top;"><img src="image00004.jpg"></td>
        </tr>

    </table>
  </div>
  <div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25;"><br>
      </div>
    </div>
    <div style="line-height: 1.25; font-weight: bold;">For Immediate Release</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-style: italic;">- GLIX1 restores TET2 activity in cancer, resulting in double stranded DNA breaks</div>
    <div style="text-align: center; line-height: 1.25; font-style: italic;">in cancer cells only -</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-style: italic;">- FDA IND clearance received for Phase 1/2a study, expected to initiate in Q1 2026 -</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-style: italic;">- Glioblastoma market opportunity estimated to be in excess of $3.8 billion</div>
    <div style="text-align: center; line-height: 1.25; font-style: italic;">annually across the US and EU5 by 2030 -</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-style: italic;">- BioLineRx affirms its cash runway into the first half of 2027 -</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-style: italic;">- Management to host conference call today, September 29<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>, at 8:30 am EDT -</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">TEL AVIV, Israel and OSLO, Norway,
        September 29, 2025 &#8211;</font> BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a Norwegian biotech company focused on small
      molecule cancer therapeutics, today announced the establishment of a joint venture (JV) to develop GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma (GBM) and other cancers. GLIX1 agonizes TET2 activity in
      cancer cells, resulting in the formation of double-stranded DNA breaks and apoptosis specifically in cancer cells.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">GLIX1, Hemispherian&#8217;s lead drug candidate, is being
        developed as a potential treatment for newly diagnosed and recurrent GBM. GLIX1 has demonstrated potent anti-tumor activity in multiple glioblastoma models, excellent blood-brain barrier penetration and a favorable safety profile in preclinical
        toxicology studies. An Investigational New Drug (IND) application was cleared by the U.S. Food and Drug Administration (FDA) in August 2025, and a Phase 1/2a study is expected to initiate in Q1 2026. GLIX1 has also been granted Orphan Drug
      Designation by both the FDA and the European Medicines Agency (EMA), underscoring the substantial unmet need in this indication. In addition, GLIX1 has shown anti-tumor
        activity in other cancer models, and early data also suggest the potential for strong synergy of GLIX1 with PARP inhibitors, particularly in homologous recombination (HR) proficient cancers. Further development in other solid tumors is being
        planned.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#8220;This joint venture combines our expertise in DNA damage response research and discovery, with BioLineRx&#8217;s proven track record of
      clinical and regulatory success,&#8221; stated Zeno Albisser, Chief Executive Officer of Hemispherian. &#8220;Glioblastoma is a notoriously challenging tumor type in urgent need of new treatment options. GLIX1 is a small molecule that crosses the
      blood-brain-barrier, has a novel mechanism of action targeting a DNA repair mechanism in cancer cells, and has demonstrated impressive efficacy and a favorable safety profile in pre-clinical models. We are eager to initiate the Phase 1/2a study as
      expeditiously as possible, and are working with leading neuro-oncology centers and the BioLineRx team to bring this promising asset to patients.&#8221;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;">&#8220;Following a comprehensive review of pipeline expansion opportunities in oncology and rare diseases, we are thrilled to have identified
      a highly innovative asset such as GLIX1, with the potential to become an effective and safe treatment option for cancer patients with high unmet needs. I could not be more excited to work alongside the Hemispherian team,&#8221; said Philip Serlin, Chief
      Executive Officer of BioLineRx. &#8220;This JV brings together highly complementary capabilities in DNA repair research, alongside clinical development and regulatory expertise, to create an entity that I believe is well positioned to bring much-needed
      innovation to the most challenging cancer types while creating shareholder value. The JV also has a first look at other molecules in Hemispherian&#8217;s pipeline, but will initially focus on GLIX1.&#8221;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Terms of the Joint Venture</div>
    <div style="text-align: justify; line-height: 1.25;">Pursuant to the terms of the JV agreement, Hemispherian will contribute the global rights of GLIX1 to the JV, and BioLineRx will be
      responsible for managing, performing and funding all JV development activities. In consideration for their respective contributions, as of the JV&#8217;s inception, Hemispherian will hold 60% of the JV&#8217;s share capital, and BioLineRx will hold a 40% stake,
      with BioLineRx&#8217;s stake increasing incrementally to a potential maximum of 70% in parallel with its continued investment in the program. The parties agreed that all funding from BioLineRx would go strictly to asset development. The JV also has a first
      look at other molecules in Hemispherian&#8217;s pipeline.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Urgent Unmet Need and Significant Commercial Opportunity in Glioblastoma</div>
    <div style="text-align: justify; line-height: 1.25;">GBM is the most common and aggressive form of primary brain cancer&#8203;. The current standard of care (SoC) treatment was established in
      2005, with only limited further advancements since. Treatment includes surgical resection, followed by radiotherapy, and concomitant and adjuvant chemotherapy (Temozolomide), yet most patients will succumb to their disease within less than 18 months
      (median OS of 12-18 months).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">GBM occurs at all ages, but peaks in the fifth and sixth decades of life, with an increasing incidence in light of the aging global
      population. New and better treatments are desperately needed aiming at improving survival, maintaining quality of life and delaying tumor progression and symptoms.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The annual incidence of GBM is expected to be approximately 18,500 patients in the U.S. and approximately 13,400 across the EU5 (France,
      Germany, Italy, Spain and the United Kingdom) by 2030. Total addressable markets across both the newly diagnosed and recurrent settings are estimated to be approximately $2.5 billion in the U.S., and approximately $1.3 billion across the 5EU at that
      time.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Phase 1/2a Study to be Conducted by World Leading Investigators in Glioblastoma</div>
    <div style="text-align: justify; line-height: 1.25;">Dr. Roger Stupp and Dr. Ditte Primdahl of the Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center at Northwestern
      University will serve as principal investigators for the study.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The Phase 1 part of the trial is expected to recruit up to 30 patients with recurrent GBM. The objective of this part is to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy&#8203;. Data from the Phase 1 part of the trial is anticipated in H1
        2027.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The Phase 2a expansion part of the trial is planned to include three population cohorts: (1) GLIX1 as monotherapy in recurrent GBM, (2)
      GLIX1 in combination with standard of care in newly diagnosed GBM patients (likely a &#8220;window of opportunity&#8221; study), and (3) GLIX1 in combination with PARP inhibitors in other solid tumors.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Conference Call and Webcast Information</div>
    </div>
    <div style="text-align: justify; line-height: 1.25;">To access the conference call, please dial +1-888-281-1167 from the&#160;U.S.&#160;or +972-3-918-0685 internationally. A live webcast and a replay
      of the call can be accessed through the&#160;<u>event page</u>&#160;on the Company's website. Please allow extra time prior to the call to visit the site and download any
      necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until&#160;October 1, 2025; please dial
      +1-888-295-2634 from the US or +972-3-925-5904 internationally.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">About Hemispherian AS</div>
    <div style="text-align: justify; line-height: 1.25;">Hemispherian AS is a pioneering biotech company developing next-generation therapeutics for aggressive cancers. The company is focused
      on developing a novel class of small molecule drugs targeting the TET2 enzyme.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The company&#8217;s lead compound, GLIX1, has a unique mechanism of action that selectively targets DNA repair pathways in tumor cells while
      sparing healthy tissue. Hemispherian has received IND clearance from the FDA to start clinical development for GLIX1. Hemispherian is based in Oslo, Norway. For more information, visit <u>www.hemispherian.com</u>.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">About BioLineRx</div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">BioLineRx Ltd.&#160;(NASDAQ/TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The
        Company's first approved product, APHEXDA&#174; (motixafortide), is indicated in the&#160;U.S.&#160;for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by&#160;Ayrmid Ltd.&#160;(globally, except Asia) and Gloria
        Biosciences (in&#160;Asia).&#160;BioLineRx has retained the rights to develop motixafortide in metastatic pancreatic cancer (PDAC) and has a Phase 2b PDAC trial currently ongoing under a collaboration with Columbia University.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">In addition, BioLineRx has established a joint venture
          with Hemispherian AS to develop GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors, for which a Phase 1/2a clinical trial will be initiated in the first quarter of 2026.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Learn more about who we are, what we do, and how we do it at&#8239;<u>www.biolinerx.com</u>, or on&#8239;<u>LinkedIn</u>.</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Forward Looking Statement</div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic;">Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking
      statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects,"
      "should," "will," and "would," and describe opinions about future events. These include statements regarding management's expectations, beliefs and intentions regarding, among other things, the potential success of the joint venture with
      Hemispherian, expectations with regard to the therapeutic potential of GLIX1 and the addressable market, expectations regarding the timeline for initiation of a Phase 1/2a study, the expected cash runway of BioLineRx, and BioLineRx's business
      strategy. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or
      achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the
      clinical development, commercialization and market acceptance of BioLineRx's therapeutic candidates, including the degree and pace of market uptake of APHEXDA for the mobilization of hematopoietic stem cells for autologous transplantation in multiple
      myeloma patients; the initiation, timing, progress and results of BioLineRx's preclinical studies, clinical trials, and other therapeutic candidate development efforts; BioLineRx's ability to advance its therapeutic candidates into clinical trials or
      to successfully complete its preclinical studies or clinical trials, whether the clinical trial results for APHEXDA will be predictive of real-world results; BioLineRx's receipt of regulatory approvals for its therapeutic candidates, and the timing
      of other regulatory filings and approvals; whether access to APHEXDA is achieved in a commercially viable manner and whether APHEXDA receives adequate reimbursement from third-party payors; BioLineRx's ability to establish, manage, and maintain
      corporate collaborations, as well as the ability of BioLineRx's collaborators to execute on their development and commercialization plans; BioLineRx's ability to integrate new therapeutic candidates and new personnel as well as new collaborations;
      the interpretation of the properties and characteristics of BioLineRx's therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business model and
      strategic plans for its business and therapeutic candidates; the scope of protection BioLineRx is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without
      infringing the intellectual property rights of others; estimates of BioLineRx's expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing; risks related to changes in healthcare laws,
      rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx's industry; BioLineRx's ability to maintain the listing of its ADSs on Nasdaq; and statements as to the impact of the political and security
      situation in Israel on BioLineRx's business, which may exacerbate the magnitude of the factors discussed above. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed
      with the Securities and Exchange Commission on March 31, 2025. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent
      date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Contacts:</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><u>BioLineRx</u></div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">United States</div>
      <div style="text-align: justify; line-height: 1.25;">Irina Koffler</div>
      <div style="text-align: justify; line-height: 1.25;">LifeSci Advisors, LLC</div>
      <div style="text-align: justify; line-height: 1.25;"><u>IR@biolinerx.com</u></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Israel</div>
      <div style="text-align: justify; line-height: 1.25;">Moran Meir</div>
      <div style="text-align: justify; line-height: 1.25;">LifeSci Advisors, LLC</div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"><u>moran@lifesciadvisors.com</u></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><u>Hemispherian</u></div>
    <div style="text-align: justify; line-height: 1.25;">Zeno Albisser</div>
    <div style="text-align: justify; line-height: 1.25;"><u>info@hemispherian.com</u></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image00003.jpg
<TEXT>
begin 644 image00003.jpg
M_]C_X  02D9)1@ ! 0$ J "H  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  Y / # 2(  A$! Q$!_\0
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M.GI]/P7ZC@W_ ))#Q$_[%^6?^E9@?-<8_P#)6>'G_8QS/_TG+C_0CHK\ZO\
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M\)>(=/\ $NFI8WWB;PSXOT>.&>^TV"*]6?0KF22T>6."2VF9)X^!_P""?_\
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M*>"HXNM]7PD:U:I"DL1C*B_>?5,)&<L7B:=!2Q-:A1G1PL)XB=.+\/\ V?\
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,)B/98JG&4Z,8O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image00004.jpg
<TEXT>
begin 644 image00004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  N , # 2(  A$! Q$!_\0
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?-97^\ZJ S?4U+110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
